<SEC-DOCUMENT>0001193125-21-012445.txt : 20210120
<SEC-HEADER>0001193125-21-012445.hdr.sgml : 20210120
<ACCEPTANCE-DATETIME>20210120162213
ACCESSION NUMBER:		0001193125-21-012445
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20210120
DATE AS OF CHANGE:		20210120

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INOVIO PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001055726
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				330969592
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-252256
		FILM NUMBER:		21539008

	BUSINESS ADDRESS:	
		STREET 1:		6769 MESA RIDGE RD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		8584103134

	MAIL ADDRESS:	
		STREET 1:		6769 MESA RIDGE RD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INOVIO BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20050404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20011116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL LTD
		DATE OF NAME CHANGE:	19980213
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d113891d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(5) <BR> Registration No. 333-252256 </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#c21128">The information in this prospectus is not complete and may be
changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and we are not soliciting an offer to buy these securities in any state or other jurisdiction where the offer or sale is not
permitted. </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#c21128">Subject to Completion
</FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#c21128">Preliminary Prospectus Supplement dated January 20, 2021 </FONT></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>PROSPECTUS&nbsp;&nbsp;&nbsp;&nbsp;SUPPLEMENT </U></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(To
Prospectus Dated January <B></B>20, 2021) </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g113891g94r84.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>$150,000,000 </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are offering
$150,000,000 of our common stock, par value $0.001 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the Nasdaq Global Select Market under the
symbol &#147;INO.&#148; On January&nbsp;19, 2021, the last reported sale price of our common stock on the Nasdaq Global Select Market was $10.10&nbsp;per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:12pt; font-family:Times New Roman"><B>Investing in our common stock involves risk. See &#147;<A HREF="#suppcov113891_1">Risk Factors</A>&#148; beginning on <FONT
STYLE="white-space:nowrap">page&nbsp;S-8</FONT> of this prospectus supplement, on page&nbsp;3 of the accompanying <A HREF="#rom110733_2">base prospectus</A> and our filings with the Securities Exchange Commission, or the SEC, that are incorporated
by reference herein and therein to read about factors you should consider before investing in our common stock. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Per&nbsp;Share</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and commissions (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;margin-left:8%;border-bottom:1px solid #000000; width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We refer you to &#147;<A HREF="#suppcov113891_3">Underwriting</A>&#148; beginning on page S-24 for additional
information regarding underwriting compensation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The underwriters may also exercise their option to purchase up to an
additional $22,500,000 of shares of common stock from us, at the public offering price, less the underwriting discount, for 30&nbsp;days after the date of this prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:12pt; font-family:Times New Roman"><B>Neither the SEC nor any state securities commission has approved or disapproved of these securities or determined if this prospectus
supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
shares will be ready for delivery on or about &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Joint Book-Running Managers </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:18pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:18pt">
<TD VALIGN="top"><B>BofA Securities</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;Jefferies</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Cantor</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Lead Manager </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Oppenheimer&nbsp;&amp; Co </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:20%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The date of this
prospectus supplement is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2021. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus Supplement </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc113891_1">ABOUT THIS PROSPECTUS SUPPLEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-ii</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc113891_2">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc113891_3">THE OFFERING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-6</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc113891_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-8</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc113891_5">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-12</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc113891_6">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-14</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc113891_7">DIVIDEND POLICY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-15</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc113891_8">DILUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-16</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc113891_9">CAPITALIZATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-18</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc113891_10">MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS OF OUR COMMON STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-20</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc113891_11">UNDERWRITING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-24</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc113891_12">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-32</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc113891_13">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-32</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc113891_14">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-33</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc113891_15">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-34</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom110733_1">INOVIO PHARMACEUTICALS, INC.</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom110733_2">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom110733_3">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom110733_4">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom110733_5">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom110733_6">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom110733_7">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom110733_8">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom110733_9">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc113891_1"></A><A NAME="suppcov113891_2"></A>ABOUT THIS PROSPECTUS
SUPPLEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This prospectus supplement is part of a registration statement that we have filed with the Securities and Exchange
Commission, or the SEC, utilizing a shelf registration process. This prospectus supplement is not complete without, and may not be utilized except in connection with, the accompanying prospectus. This prospectus supplement provides supplemental
information regarding us and updates certain information contained in the accompanying prospectus and describes the specific terms of this offering. The accompanying prospectus gives more general information, some of which may not apply to this
offering. We incorporate important information into this prospectus supplement and the accompanying prospectus by reference. You should read this prospectus supplement and the accompanying prospectus together with additional information described
below under the headings &#147;Where You Can Find More Information&#148; and &#147;Incorporation of Certain Documents by Reference.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Any statement contained in a document incorporated or deemed to be incorporated by reference in this prospectus supplement or the accompanying
prospectus will be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference in this prospectus supplement or the
accompanying prospectus modifies or supersedes that statement. Any statement so modified or superseded will not be deemed, except as so modified or superseded, to constitute a part of this prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">You should rely only on the information contained in this prospectus supplement, the accompanying prospectus, the documents incorporated by
reference and any free writing prospectus that we may authorize for use in connection with the offering. We have not, and the underwriters have not, authorized any other person to provide you with different information. If anyone provides you with
different or inconsistent information, you should not rely on it. We are not, and the underwriters are not, making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. The distribution of this prospectus
supplement and the offering of the common stock in certain jurisdictions may be restricted by law. Persons outside the United States who come into possession of this prospectus supplement must inform themselves about, and observe any restrictions
relating to, the offering of the common stock and the distribution of this prospectus supplement outside the United States. This prospectus supplement does not constitute, and may not be used in connection with, an offer to sell, or a solicitation
of an offer to buy, any securities offered by this prospectus supplement by any person in any jurisdiction in which it is unlawful for such person to make such an offer or solicitation. You should assume that the information appearing in this
prospectus supplement is accurate as of the date on the front cover of this prospectus supplement only. Our business, financial condition, results of operations and prospects may have changed since that date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Unless the context otherwise requires, all references in this prospectus supplement to &#147;Inovio,&#148; &#147;we,&#148; &#147;us,&#148;
&#147;our,&#148; &#147;the Company&#148; or similar words refer to Inovio Pharmaceuticals, Inc., together with our consolidated subsidiaries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc113891_2"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights information contained or incorporated by reference in this prospectus supplement. Because it is only a summary, it
does not contain all of the information that may be important to you or that you should consider before making an investment in our common stock. You should carefully read the entire prospectus and the accompanying prospectus, including the
information contained under the caption &#147;Risk Factors&#148; and elsewhere in our most recent Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> the information under &#147;Risk Factors&#148; beginning on page <FONT
STYLE="white-space:nowrap">S-8</FONT> of this prospectus supplement and other information that we file from time to time with the SEC as well as the financial statements and related notes and the other information incorporated by reference herein,
before making an investment decision. See &#147;Where You Can Find More Information&#148; and &#147;Incorporation of Certain Documents by Reference&#148; in this prospectus supplement. This prospectus supplement may add to, update or change
information in the accompanying prospectus. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Our Company </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure and protect people from
diseases associated with human papillomavirus, or HPV, cancer and infectious diseases. Our DNA medicine pipeline is composed of three types of product candidates: DNA vaccines, DNA immunotherapies and DNA encoded monoclonal antibodies. In clinical
trials, we have demonstrated that a DNA medicine can be delivered directly into cells in the body via our proprietary smart device to consistently activate robust and fully functional T cell and antibody responses against targeted cancers and
pathogens. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our novel DNA medicine candidates are made using our proprietary SynCon technology that creates optimized plasmids, which are
circular strands of DNA that can produce antigens independently inside a cell to help the person&#146;s immune system recognize and destroy cancerous or virally infected cells. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our hand-held CELLECTRA smart delivery devices provide optimized uptake of our DNA medicines within the cell, overcoming a key limitation of
other <FONT STYLE="white-space:nowrap">DNA-based</FONT> technology approaches. Human data to date have shown a favorable tolerability profile of our DNA medicines delivered directly into cells in the body using the CELLECTRA smart delivery device in
more than 7,000 administrations across approximately 2,500 patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our corporate strategy is to advance, protect, and provide our novel
DNA medicines to meet urgent and emerging global health needs. We continue to advance and validate an array of DNA medicine candidates that target <FONT STYLE="white-space:nowrap">COVID-19,</FONT> <FONT STYLE="white-space:nowrap">HPV-related</FONT>
diseases, cancer and infectious diseases. We aim to advance these candidates through commercialization and continue to leverage third-party resources through collaborations and partnerships, including product license agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine, The Bill&nbsp;&amp; Melinda Gates Foundation,
Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, GeneOne Life Science, HIV Vaccines Trial Network, the U.S. Defense Threat Reduction Agency&#146;s Medical CBRN Defense
Consortium, International Vaccine Institute, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences,
Regeneron Pharmaceuticals, Thermo Fisher Scientific, Richter-Helm BioLogics, the University of Pennsylvania, the Walter Reed Army Institute of Research and The Wistar Institute. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We or our collaborators are currently conducting or planning clinical studies of our DNA medicines for
<FONT STYLE="white-space:nowrap">HPV-associated</FONT> precancers, including cervical, vulvar and anal dysplasia; <FONT STYLE="white-space:nowrap">HPV-associated</FONT> cancers, including head&nbsp;&amp; neck, cervical, anal, penile, vulvar and
vaginal; other <FONT STYLE="white-space:nowrap">HPV-associated</FONT> disorders, such as recurrent </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome; Lassa fever; Zika virus; and the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> virus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">All of our product candidates are in the research and development phase. We have
not generated any revenues from the sale of any products, and we do not expect to generate any such revenues for at least the next several years. We earn revenue from license fees and milestone revenue and collaborative research and development
agreements. Our product candidates will require significant additional research and development efforts, including extensive preclinical and clinical testing. All product candidates that we advance to clinical testing will require regulatory
approval prior to commercial use and will require significant costs for commercialization. We may not be successful in our research and development efforts, and we may never generate sufficient product revenue to be profitable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Our Pipeline </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The table
below summarizes the status of our product candidate development programs: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g113891g51m17.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Recent Developments </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">INO-4800</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In December 2020, we dosed our first subject in a Phase 2 clinical trial evaluating DNA medicine <FONT
STYLE="white-space:nowrap">INO-4800,</FONT> our <FONT STYLE="white-space:nowrap">COVID-19</FONT> vaccine candidate, as part of our Phase 2/3 clinical trial, called INNOVATE. The Phase 2 segment of the trial will enroll approximately 400 participants
who are 18 years or older.&nbsp;In addition, in collaboration with Advaccine Biopharmaceuticals Suzhou Co., Ltd. (Advaccine), we dosed the first subject in our Phase 2 clinical trial in China. The Phase 2 clinical trial being conducted in China is
independent of the INNOVATE Phase 2/3 clinical trial of <FONT STYLE="white-space:nowrap">INO-4800</FONT> being advanced in the United States and will enroll approximately 640 participants who are 18 years or older. Advaccine is conducting and
funding the Phase 2 trial in China. Our planned clinical development of <FONT STYLE="white-space:nowrap">INO-4800</FONT> is currently on partial clinical hold and we may not commence our planned Phase 3 clinical trial of <FONT
STYLE="white-space:nowrap">INO-4800</FONT> until we satisfactorily resolve the Food and Drug Administration&#146;s, or the FDA&#146;s, questions relating to our CELLECTRA 2000 delivery device. See &#147;Risk Factors&#151;<I>Our planned clinical
development of our potential <FONT STYLE="white-space:nowrap">COVID-19</FONT> vaccine has been placed on partial clinical hold by the FDA, which may cause delays in the commencement of our planned Phase 3 clinical trial or completion of clinical
testing, both of which could result in increased costs to us and delay or limit our ability to proceed to commercialization and generate revenues</I>.&#148; </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We entered into a collaboration and license agreement in December 2020 with Advaccine granting Advaccine the
exclusive right to develop, manufacture and commercialize our vaccine <FONT STYLE="white-space:nowrap">candidate,&nbsp;INO-4800,</FONT> within the territories of China, Taiwan, Hong Kong and Macau. As part of the collaboration, Advaccine has also
granted us a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license to certain DNA vaccine manufacturing processes. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We expanded our global manufacturing consortium by entering into an agreement with Kaneka Eurogentec S.A., an
affiliate of Kaneka Corporation, for Eurogentec to manufacture <FONT STYLE="white-space:nowrap">INO-4800</FONT> at our GMP (good manufacturing practice) production facilities. In addition to Kaneka Eurogentec, we have entered into supply agreements
with Thermo Fisher Scientific, Richter-Helm BioLogics and Ology Biosciences as part of our global manufacturing consortium that we are assembling in connection with the clinical and potential commercial supply for our
<FONT STYLE="white-space:nowrap">COVID-19</FONT> vaccine candidate and other product candidates. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">HPV-Targeted</FONT> Candidates </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In January 2021, we announced positive efficacy results for an open-label Phase 2 trial of <FONT
STYLE="white-space:nowrap">VGX-3100</FONT> to treat <FONT STYLE="white-space:nowrap">HPV-16</FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HPV-18-associated</FONT></FONT> vulvar dysplasia. A 25% or more reduction in <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HPV-16/18-associated</FONT></FONT> vulvar high-grade squamous intraepithelial lesion, or HSIL, was observed for 63% of trial participants (12 of 19) treated with <FONT
STYLE="white-space:nowrap">VGX-3100</FONT> at six months post-treatment. Three out of 20 participants with histology data (15%) resolved their vulvar HSIL and had no <FONT STYLE="white-space:nowrap">HPV-16/18</FONT> virus detectable in the healed
area. By comparison, the spontaneous resolution of vulvar HSIL caused by <FONT STYLE="white-space:nowrap">HPV-16/18</FONT> is estimated to be only 2%. The trial also showed VGX3100 to be well-tolerated. Based upon these results, we are planning to
pursue Phase 3 development. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In December 2020, we announced positive Phase 2 efficacy results demonstrating that DNA medicine <FONT
STYLE="white-space:nowrap">VGX-3100,</FONT> our lead immunotherapy asset, showed resolution of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HPV-16/18-associated</FONT></FONT> precancerous anal lesions in 50% (11 of 22) of
subjects six months following the start of treatment. The open label, single arm trial also showed <FONT STYLE="white-space:nowrap">VGX-3100</FONT> to be well-tolerated in treating men and women with
<FONT STYLE="white-space:nowrap">HPV16-/18-associated</FONT> anal dysplasia. We plan to pursue a registrational Phase 3 clinical trial for
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HPV-16-/18-associated</FONT></FONT></FONT> anal dysplasia as well as to apply for rare and orphan disease designation for this indication in 2021.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In November 2020, we dosed our first subject with DNA medicine <FONT STYLE="white-space:nowrap">INO-3107</FONT>
in a Phase 1/2 clinical trial for the treatment of Recurrent Respiratory Papillomatosis. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Proceedings </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On December&nbsp;7, 2020, GeneOne Life Science, Inc., or GeneOne, filed a complaint in the Court of Common Pleas of Montgomery County,
Pennsylvania against us, alleging that we had breached the CELLECTRA Device License Agreement, or the Agreement, between GeneOne and the Company. We terminated the Agreement on October&nbsp;9, 2020. The complaint asserts claims for breach of
contract, declaratory judgment, unfair competition, and unjust enrichment. The complaint seeks injunctive relief, an accounting, damages, disgorgement of profits, attorneys&#146; fees, interest, and other relief from us. We intend to vigorously
defend ourselves against GeneOne&#146;s claims. Please see our most recent Quarterly Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q,</FONT> which we incorporate by reference herein, for additional discussion of our legal proceedings. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain Preliminary Financial Results as of December&nbsp;31, 2020 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2020, we preliminarily estimate that our cash, cash equivalents and short-term investments was approximately $412
million and that we had 186,851,493 shares of common stock outstanding. This information is unaudited and preliminary, is subject to completion of financial closing procedures that could result in changes to the amount and does not present all
information necessary for an understanding of our financial condition as of December&nbsp;31, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Selected Risks Associated with Our
Business </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our business is subject to a number of risks of which you should be aware before making an investment decision. These risks
are discussed more fully in the &#147;Risk Factors&#148; section of this prospectus supplement immediately following this prospectus supplement summary and those described under similar headings in the documents incorporated by reference into this
prospectus supplement. These risks include the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have incurred significant losses since our inception. We expect to incur losses over the next several years
and may never achieve or maintain profitability. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our planned clinical development of our potential <FONT STYLE="white-space:nowrap">COVID-19</FONT> vaccine has
been placed on partial clinical hold by the FDA, which may cause delays in the commencement of our planned Phase 3 clinical trial or completion of clinical testing, both of which could result in increased costs to us and delay or limit our ability
to proceed to commercialization and generate revenues. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">There can be no assurance our potential <FONT STYLE="white-space:nowrap">COVID-19</FONT> vaccine would be granted
an Emergency Use Authorization by the FDA. If we are unable to obtain Emergency Use Authorization, we will be unable to sell our product in the near future and will be required to pursue the biologic licensure process, which is lengthy and
expensive. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">There can be no assurance of market acceptance for our potential <FONT STYLE="white-space:nowrap">COVID-19</FONT>
vaccine or other product candidates. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are currently subject to litigation and may become subject to additional litigation relating to our potential <FONT
STYLE="white-space:nowrap">COVID-19</FONT> vaccine, which could harm our business, financial condition and reputation. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have limited sources of revenue and our success is dependent on our ability to develop our DNA vaccines, DNA
immunotherapies, dMAb and electroporation equipment. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">None of our human vaccine candidates, including <FONT STYLE="white-space:nowrap">INO-4800,</FONT> or our
immunotherapy and dMAb product candidates have been approved for sale, and we may never develop commercially successful vaccine, immunotherapy or monoclonal antibody products. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We will need substantial additional capital to develop our DNA vaccine, DNA immunotherapy and dMAb programs and
electroporation delivery technology. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">It is difficult and costly to generate and protect our intellectual property and our proprietary technologies,
and we may not be able to ensure their protection. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We face intense and increasing competition and many of our competitors have significantly greater resources and
experience. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we lose or are unable to secure collaborators or partners, or if our collaborators or partners do not apply
adequate resources to their relationships with us, our product development and potential for profitability will suffer. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our business could be adversely affected by the effects of health epidemics, including the global <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Our Corporate Information </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We were incorporated under the laws of the State of Delaware in June 2001. Our principal executive offices are located at 660 W. Germantown
Pike, Suite 110, Plymouth Meeting, Pennsylvania 19462. Our telephone number is (267) <FONT STYLE="white-space:nowrap">440-4200.</FONT> Our common stock is listed on the Nasdaq Global Select Market under the symbol &#147;INO.&#148; Our internet
website address is <I>www.inovio.com</I>. The information contained on our website is not incorporated by reference into this prospectus, and you should not consider any information contained on, or that can be accessed through, our website as part
of this prospectus or in deciding whether to purchase our securities. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc113891_3"></A>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock offered by us </P></TD>
<TD>$150,000,000 shares of common stock </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Underwriters&#146; option to purchase additional shares of common stock </P></TD>
<TD>We have granted the underwriters a <FONT STYLE="white-space:nowrap">30-day</FONT> option to purchase up to $22,500,000 additional shares at the public offering price less underwriting discounts and commissions. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock to be outstanding immediately after this offering </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares (or &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares if the underwriters exercise in full their option to purchase additional ordinary
shares). </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </P></TD>
<TD>We currently intend to use the net proceeds from this offering for the development of our clinical pipeline, including clinical development expenses relating to <FONT STYLE="white-space:nowrap">INO-4800</FONT> and research and development
expenses, and for general corporate purposes, including working capital and general and administrative expenses. See &#147;Use of Proceeds&#148; on page <FONT STYLE="white-space:nowrap">S-14.</FONT> </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk factors </P></TD>
<TD>See &#147;Risk Factors&#148; beginning on page <FONT STYLE="white-space:nowrap">S-8</FONT> of this prospectus supplement and the other information included in, or incorporated by reference into, this prospectus supplement for a discussion of
certain factors you should carefully consider before deciding to invest in our ordinary shares. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Nasdaq Global Select Market symbol </P></TD>
<TD>&#147;INO&#148; </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The above discussion is based on 186,392,777 shares of our common stock outstanding, which represents
167,528,435 shares of our common stock outstanding as of September&nbsp;30, 2020, plus (i)&nbsp;10,874,756 shares issued in connection with sales from our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">at-the-market</FONT></FONT>
program between October&nbsp;1, 2020 and December&nbsp;31, 2020 and (ii)&nbsp;7,989,586 shares issued as a result of the conversion of $43 million of our outstanding 6.5% Convertible Senior Notes due 2024, or the Notes, between October&nbsp;1, 2020
and December&nbsp;31, 2020, but excludes: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">9,290,347 shares issuable upon exercise of outstanding stock options pursuant to our stock incentive plans, at a
weighted average option exercise price of $6.66 per share as of September&nbsp;30, 2020; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,586,915 shares issuable upon vesting of service-based restricted stock units outstanding under our stock
incentive plans as of September&nbsp;30, 2020; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">663,353 shares issuable upon vesting of performance-based restricted stock units outstanding under our stock
incentive plans as of September&nbsp;30, 2020; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3,309 shares issuable upon the conversion of outstanding Series C Cumulative Convertible Preferred Stock as of
September&nbsp;30, 2020; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3,049,988 shares issuable upon the conversion of outstanding Notes, which reflects the conversion of $43 million
of Notes between October&nbsp;1, 2020 and December 31, 2020 for 7,989,586 shares </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD VALIGN="top">of common stock; and </TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">shares that may become issuable upon the conversion of outstanding 1.0% Convertible Bonds due 2024, or the
December 2019 Bonds. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Except as otherwise indicated, all information in this prospectus assumes: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no exercise or conversion of outstanding stock options, restricted stock units, convertible preferred stock or
convertible senior notes or bonds; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no exercise by the underwriters of their option to purchase additional shares of common stock.
</P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc113891_4"></A><A NAME="suppcov113891_1"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>An investment in our common stock is subject to numerous risks as discussed more fully below and under the caption &#147;Risk Factors&#148;
in the accompanying prospectus and our most recent Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> which we incorporate by reference herein, and other information that we file from time to time with the SEC after the date of
this prospectus supplement and which we incorporate by reference herein. Any of these risks could adversely affect our financial condition and results of operations or our ability to execute our business strategy. You should read and consider
carefully all the information set forth and incorporated by reference in this prospectus supplement and the accompanying prospectus before deciding whether to invest in our common stock. The risks and uncertainties we have described are not the only
ones facing our company. Additional risks and uncertainties not presently known to us or that we currently consider immaterial may also affect our business operations. See &#147;Incorporation of Certain Documents by Reference.&#148; </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our <FONT STYLE="white-space:nowrap">COVID-19</FONT> Vaccine Candidate </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our planned clinical development of <FONT STYLE="white-space:nowrap">INO-4800</FONT> as a potential <FONT STYLE="white-space:nowrap">COVID-19</FONT>
vaccine has been placed on partial clinical hold by the FDA, which may cause delays in the commencement of our planned Phase 3 clinical trial or completion of clinical testing, both of which could result in increased costs to us and delay or limit
our ability to proceed to commercialization and generate revenues. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our planned clinical development of <FONT
STYLE="white-space:nowrap">INO-4800</FONT> as a potential <FONT STYLE="white-space:nowrap">COVID-19</FONT> vaccine has been placed on partial clinical hold by the FDA. We may not commence our planned Phase 3 clinical trial of <FONT
STYLE="white-space:nowrap">INO-4800</FONT> until we satisfactorily resolve the FDA&#146;s remaining questions relating to our CELLECTRA 2000 delivery device to be used in connection with <FONT STYLE="white-space:nowrap">INO-4800</FONT> in our Phase
3 clinical trials and commercial product, if authorized or licensed by the FDA. We are actively working to address the FDA&#146;s questions and plan to respond in March 2021, after which the FDA will have up to 30 days to notify us of its decision
as to whether our Phase 3 trial may proceed. However, there can be no assurance regarding the timing of the FDA&#146;s agreement to lift the partial clinical hold or that we will ultimately be successful in obtaining any such determination from the
FDA to do so. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Delays in the commencement of our Phase 3 trial or completion of ongoing clinical testing for <FONT
STYLE="white-space:nowrap">INO-4800</FONT> could significantly affect our product development costs. We do not know whether our planned Phase 3 clinical trial will begin on time or be completed on schedule, if at all. In addition, our ongoing
clinical trials for <FONT STYLE="white-space:nowrap">INO-4800</FONT> may not be completed on schedule, or at all, and could be placed on additional holds by regulators for reasons unrelated to our current hold. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our Phase 3 trial for <FONT STYLE="white-space:nowrap">INO-4800</FONT> will require interim data results at various points throughout the
trial. Our clinical trials may therefore also be delayed as a result of ambiguous or negative interim results. Even if our interim results related to our <FONT STYLE="white-space:nowrap">INO-4800</FONT> are positive, there can be no assurance that
our topline results will be consistent with the interim results. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If we experience delays in completion of, or if we terminate, any of our
clinical trials relating to <FONT STYLE="white-space:nowrap">INO-4800,</FONT> the commercial prospects for our product candidate may be harmed and our ability to generate product revenues will be delayed. In addition, many of the factors that cause,
or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate. Further, delays in the commencement or completion of clinical trials may adversely affect
the trading price of our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>There can be no assurance that the product we are developing for
<FONT STYLE="white-space:nowrap">COVID-19</FONT> would be granted an Emergency Use Authorization by the FDA if we were to decide to apply for an Emergency Use Authorization. If we do not apply for an Emergency Use Authorization or, if we do apply
and no Emergency Use Authorization is granted or, once granted, it is terminated, we will be unable to sell our product in the near future and will be required to pursue the biologic licensure process, which is lengthy and expensive. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may seek an Emergency Use Authorization, or EUA, from the FDA. If we apply and it is granted, an EUA will authorize us to market and sell
our <FONT STYLE="white-space:nowrap">COVID-19</FONT> vaccine under certain conditions of authorization as long as the public health emergency exists. The FDA expects that companies which receive an EUA for
<FONT STYLE="white-space:nowrap">COVID-19</FONT> vaccines will proceed to licensure of their vaccine products under a full Biologics License Application. The FDA may issue an EUA during a Public Health Emergency if the agency determines that the
potential benefits of a product outweigh the potential risks and if other regulatory criteria are met. There is no guarantee that we will apply for an EUA or, if we do apply, that we will be able to obtain an EUA. If an EUA is granted, we will rely
on the FDA policies and guidance governing vaccines authorized in this manner in connection with the marketing and sale of our product. If these policies and guidance change unexpectedly and/or materially or if we misinterpret them, potential sales
of our product could be adversely impacted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">An EUA authorizing the marketing and sale of our product will terminate upon expiration of
the Public Health Emergency, which is a determination made by the Secretary of Health and Human Services. The FDA may also terminate an EUA if safety issues or other concerns about our product arise or if we fail to comply with the conditions of
authorization. If we apply for an EUA, the failure to obtain such authorization or the termination of such an authorization, if obtained, would adversely impact our ability to market and sell our <FONT STYLE="white-space:nowrap">COVID-19</FONT>
vaccine, which could adversely impact our business, financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>There can be no assurance of market acceptance
for our potential <FONT STYLE="white-space:nowrap">COVID-19</FONT> vaccine. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The commercial success of our <FONT
STYLE="white-space:nowrap">COVID-19</FONT> treatment will depend upon its acceptance as efficacious, safe, cost-effective and medically necessary by healthcare providers, patients, the medical community and third-party payers. There can be no
assurance our <FONT STYLE="white-space:nowrap">COVID-19</FONT> vaccine candidate will gain market acceptance on a timely basis, if at all. Healthcare providers and patients may choose <FONT STYLE="white-space:nowrap">COVID-19</FONT> vaccines that
have already been authorized or licensed by the FDA and are distributed by our competitors, which include major pharmaceutical companies that have substantially greater resources as well as other biotechnology companies. Third party payers may
prefer competitor products when making formulary and reimbursement decisions. If our product does gain market acceptance, there is no guarantee that we will be able to maintain it as new vaccines and therapeutic products enter the market. The United
States and other countries around the world have recently begun to authorize and commence distributing <FONT STYLE="white-space:nowrap">COVID-19</FONT> vaccines in their jurisdictions. The broad distribution of
<FONT STYLE="white-space:nowrap">COVID-19</FONT> vaccines may reduce demand for our potential <FONT STYLE="white-space:nowrap">COVID-19</FONT> vaccine as it may no longer be considered medically necessary. Failure to achieve and maintain market
acceptance will have a material adverse impact on our business, financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are currently subject to
litigation and may become subject to additional litigation relating to our potential <FONT STYLE="white-space:nowrap">COVID-19</FONT> vaccine, which could harm our business, financial condition and reputation. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may have actions brought against us by stockholders relating to past transactions, changes in our stock price or other matters. For
example, during 2020, numerous purported shareholder class action complaints were filed against us, naming us and our directors and executive officers as defendants, and alleging that we made materially false and misleading statements regarding the
development of our <FONT STYLE="white-space:nowrap">INO-4800</FONT> vaccine candidate against <FONT STYLE="white-space:nowrap">COVID-19</FONT> in violation of certain federal securities laws. The defense of our existing and potential future lawsuits
and providing responses to related governmental inquiries and investigations could also result in diversion of our management&#146;s time and attention away from business operations, which could have an adverse impact on our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to this Offering </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If you purchase shares of common stock in this offering, you will suffer immediate dilution of your investment. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The price of our common stock to be sold in this offering is substantially higher than the net tangible book value per share of our common
stock. Therefore, if you purchase shares of our common stock in this offering, you will pay a price per share that substantially exceeds our net tangible book value per share after this offering. Based on the public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, you will experience immediate dilution of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, representing the difference
between our pro forma as adjusted net tangible book value per share after giving effect to this offering and the public offering price. To the extent outstanding options are exercised or shares of our common stock are issued upon the conversion of
our outstanding Notes or December 2019 Bonds, you will incur further dilution. For additional information on the dilution that you will experience immediately after this offering, see the section titled &#147;Dilution.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have broad discretion in the use of the net proceeds from this offering and may invest or spend the proceeds in ways with which you do not agree and
in ways that may not yield a return on your investment. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Although we currently intend to use the net proceeds from this offering,
together with our existing cash and cash equivalents, in the manner described in the section titled &#147;Use of Proceeds&#148; in this prospectus<B></B>&nbsp;supplement, our management will have broad discretion in the application of the net
proceeds from this offering and could spend the proceeds in ways that do not improve our results of operations or enhance the value of our common stock. You will not have the opportunity to influence our decisions on how to use our net proceeds from
this offering. The failure by our management to apply these funds effectively could result in financial losses that could harm our business, cause the price of our common stock to decline and delay the development of our product candidates. Pending
their use, we may invest the net proceeds from this offering in a manner that does not produce income or that loses value.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Conversion of the Notes
and/or the December 2019 Bonds will dilute the ownership interest of existing stockholders and may otherwise depress the price of our common stock. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">During 2019, we sold $78.5&nbsp;million aggregate principal amount of our Notes, as well as $4.1&nbsp;million aggregate principal amount of
our December 2019 Bonds. Between October&nbsp;1, 2020 and December&nbsp;31, 2020, $43.0&nbsp;million aggregate principal amount of the Notes also converted into shares of our common stock, leaving $16.4 million aggregate principal amount of the
Notes remaining as of December&nbsp;31, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The conversion of some or all of the Notes or December 2019 Bonds will dilute the ownership
interests of existing stockholders to the extent we deliver shares of our common stock upon conversion of any of the Notes. The Notes may become in the future convertible at the option of the holders of the Notes prior to November&nbsp;1, 2023 under
certain circumstances as provided in the indenture governing the Notes. The December 2019 Bonds may become in the future convertible at the option of the holders of the December 2019 Bonds starting December&nbsp;31, 2020. Any sales in the public
market of the common stock issuable upon such conversion could adversely affect prevailing market prices of our common stock. In addition, the existence of the Notes may encourage short selling by market participants because the conversion of the
Notes could be used to satisfy short positions, or anticipated conversion of the Notes into shares of our common stock could depress the price of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future sales or other issuances of our common stock could depress the market for our common stock. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Sales of a substantial number of shares of our common stock, or the perception by the market that those sales could occur, could cause the
market price of our common stock to decline or could make it more difficult for us to raise funds through the sale of equity in the future. In connection with this offering, we, and our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
executive officers and directors have entered into <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements for a period of 90 days following this offering. These
<FONT STYLE="white-space:nowrap">lock-up</FONT> obligations may be released prior to the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period at the sole discretion of the representatives of the underwriters. See
&#147;Underwriting&#148; beginning on page <FONT STYLE="white-space:nowrap">S-24</FONT> of this prospectus supplement for additional information. Upon expiration or earlier release of these <FONT STYLE="white-space:nowrap">lock-ups,</FONT> we and
our executive officers and directors, and their applicable affiliates, may sell shares into the market, which could adversely affect the market price of shares of our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc113891_5"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This prospectus supplement, the accompanying prospectus, and the other documents we have filed with the SEC that are incorporated by
reference herein contain &#147;forward-looking statements&#148; within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended, or the Securities Act, and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, or the
Exchange Act, and such forward-looking statements involve risks and uncertainties. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as
&#147;anticipate,&#148; &#147;believe,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;estimate,&#148; &#147;expects,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;might,&#148; &#147;plan,&#148; &#147;potential,&#148; &#147;predict,&#148;
&#147;project,&#148; &#147;should,&#148; &#147;will,&#148; &#147;would&#148; or the negative or plural of those terms, and similar expressions intended to identify statements about the future, although not all forward-looking statements contain
these words. These statements are only predictions and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the
information expressed or implied by these forward-looking statements. In addition, statements like &#147;we believe&#148; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information
available to us as of the date of this prospectus supplement, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that
we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results,
levels of activity, performance or achievements. Moreover, neither we, nor any other person, assume responsibility for the accuracy and completeness of the forward-looking statements. Except as required by law, we are under no obligation to update
any of the forward-looking statements after the filing of this prospectus supplement or the accompanying prospectus to conform such statements to actual results or to changes in our expectations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Such statements are based on currently available operating, financial and competitive information and are subject to various risks,
uncertainties and assumptions that could cause actual results to differ materially from those anticipated or implied in our forward-looking statements due to a number of factors including, but not limited to, those set forth under the sections
entitled &#147;Risk Factors&#148; in this prospectus supplement or the accompanying prospectus, in our most recent Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> as well as any amendments or supplements thereto filed with the
SEC. We qualify all of the information presented or incorporated by reference in this prospectus supplement and the accompanying prospectus, and particularly our forward-looking statements, by these cautionary statements. In particular, you should
note the following risk factors that could cause actual results to differ from those contained in the forward-looking statements include but are not limited to: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our history of losses; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our lack of products that have received regulatory approval; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">uncertainties inherent in clinical trials and product development programs, including but not limited to the
outcome of the partial clinical hold on our clinical trial for our potential <FONT STYLE="white-space:nowrap">COVID-19</FONT> vaccine, fact that <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical results may not be indicative of
results achievable in other trials or for other indications, that results from one study may not necessarily be reflected or supported by the results of other similar studies, that results from an animal study may not be indicative of results
achievable in human studies, that clinical testing is expensive and can take many years to complete, that the outcome of any clinical trial is uncertain and failure can occur at any time during the clinical trial process, and that our
electroporation technology and DNA vaccines may fail to show the desired safety and efficacy traits in clinical trials; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of funding; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to manufacture vaccine candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish or maintain collaborations, licensing or other arrangements; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability or potential availability of alternative therapies or treatments for the conditions we or our
collaborators target, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that we and our collaborators hope to develop; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether our proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of
others or can withstand claims of invalidity; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of government healthcare legislation and proposals; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the outcome of current or future litigation, and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our use of the proceeds from any offerings under this prospectus. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">You should refer to the risks and uncertainties described in the &#147;Risk Factors&#148; section contained in this prospectus supplement, the
accompanying prospectus and any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus supplement and the accompanying prospectus, for a discussion of important
factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. Given these risks, uncertainties and other factors, many of which are beyond our control, we cannot assure you that the
forward-looking statements in this prospectus supplement and the accompanying prospectus will prove to be accurate, and you should not place undue reliance on these forward-looking statements. Furthermore, if our forward-looking statements prove to
be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our
objectives and plans in any specified time frame, or at all. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc113891_6"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We estimate that the net proceeds from this offering will be approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million if the underwriters&#146; option to purchase additional shares is
exercised in full), after deducting the underwriters&#146; fees and estimated expenses of the offering payable by us. We currently intend to use the net proceeds from this offering primarily for the development of our clinical pipeline, including
clinical development expenses relating to <FONT STYLE="white-space:nowrap">INO-4800,</FONT> research and development expenses and for general corporate purposes, including working capital, general and administrative expenses and manufacturing
expenses. Although we currently have no specific agreements, commitments or understandings with respect to any acquisition or investment, we evaluate acquisition and investment opportunities and may engage in related discussions with other companies
from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The amounts and timing of these expenditures will depend on a number of factors, such as the timing and progress of
our commercialization activities, research and development efforts, the timing of regulatory review and approval of our product candidates, the timing and progress of any partnering efforts, and the competitive environment for our product
candidates. As of the date of this prospectus supplement, we cannot specify with certainty all of the particular uses for the net proceeds from this offering. Accordingly, our management will have broad discretion in the application of these
proceeds. Pending application of the net proceeds as described above, we intend to temporarily invest the proceeds in short term, interest-bearing instruments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc113891_7"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have never declared or paid any dividends on our common stock. We anticipate that we will retain all of our future earnings, if any, for
use in the operation and expansion of our business and do not anticipate paying cash dividends in the foreseeable future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc113891_8"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If you invest in our common stock in this offering, your interest will be diluted immediately to the extent of the difference between the
public offering price per share you will pay in this offering and the as adjusted net tangible book value per share of our common stock after this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our historical net tangible book value as of September&nbsp;30, 2020 was $310&nbsp;million, or $1.85 per share of common stock. Historical net
tangible book value per share represents the amount of our total tangible assets less total liabilities, divided by the number of shares of our common stock outstanding on September&nbsp;30, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our pro forma net tangible book value as of September&nbsp;30, 2020 was $470&nbsp;million, or $2.52&nbsp;per share, based on the total number
of shares of our common stock outstanding as of September&nbsp;30, 2020. Pro forma net tangible book value per share is determined by dividing our total tangible assets, less total liabilities, by the number of shares of our common stock outstanding
as of September&nbsp;30, 2020, after giving effect to (i)&nbsp;10,874,756 shares issued in connection with sales from our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">at-the-market</FONT></FONT> program between October&nbsp;1,
2020 and December&nbsp;31, 2020 and (ii)&nbsp;7,989,586 shares issued as a result of the conversion of $43&nbsp;million of our Notes between October&nbsp;1, 2020 and December 31, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">After giving effect to our issuance and sale of shares of common stock in this offering at a public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, and after deducting the underwriting discounts and commissions and estimated offering expenses payable by us, our pro forma as adjusted net
tangible book value as of September&nbsp;30, 2020 would have been $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, or
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. This represents an immediate increase in pro forma as adjusted net tangible book value per share of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to existing stockholders and immediate dilution of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in
as adjusted net tangible book value per share to new investors purchasing common stock in this offering. Dilution per share to new investors is determined by subtracting as adjusted net tangible book value per share after this offering from the
public offering price per share paid by new investors. The following table illustrates this per share dilution to the new investors purchasing shares of common stock in this offering without giving effect to the option to purchase additional shares
granted to the underwriters: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net tangible book value per share as of September&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro&nbsp;forma increase in net tangible book value per share as of September&nbsp;30,
2020<BR>attributable to the pro&nbsp;forma transactions described above</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro&nbsp;forma net tangible book value per share as of September&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in pro forma net tangible book value per share attributable to sale of shares
of<BR>common stock in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma as adjusted net tangible book value per share after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The calculations above are based upon 167,528,435 shares of common stock outstanding as of September&nbsp;30,
2020 and exclude: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">9,290,347 shares issuable upon exercise of outstanding stock options pursuant to our stock incentive plans, at a
weighted average option exercise price of $6.66 per share as of September&nbsp;30, 2020; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,586,915 shares issuable upon vesting of service-based restricted stock units outstanding under our stock
incentive plans as of September&nbsp;30, 2020; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">663,353 shares issuable upon vesting of performance-based restricted stock units outstanding under our stock
incentive plans as of September&nbsp;30, 2020; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3,309 shares issuable upon the conversion of outstanding Series&nbsp;C Cumulative Convertible Preferred Stock as
of September&nbsp;30, 2020; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">11,039,574 shares issuable upon the conversion of the Notes outstanding as of September&nbsp;30, 2020, prior to
the conversion of $43&nbsp;million of Notes between October&nbsp;1, 2020 and December&nbsp;31, 2020 for 7,989,586 shares of common stock; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">shares that may become issuable upon the conversion of outstanding December 2019 Bonds. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If the underwriters exercise in full their option to purchase up to additional shares of common stock at the public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the pro forma as adjusted net tangible book value after this offering would be
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, representing an increase in pro forma net tangible book value of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share to existing stockholders and immediate dilution in pro forma net tangible book value of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share to investors purchasing our common stock in this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">To the extent that options or restricted stock units outstanding as of September&nbsp;30, 2020 have been or may be exercised or other shares
issued, including as the result of the conversion of the conversion of the Notes or December 2019 Bonds, investors purchasing our common stock in this offering may experience further dilution. In addition, we may choose to raise additional capital
due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. To the extent that additional capital is raised through the sale of equity or convertible debt securities,
the issuance of these securities could result in further dilution to our stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc113891_9"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table sets forth our cash and cash equivalents, indebtedness and capitalization as of September&nbsp;30, 2020: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on an actual basis; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on a pro forma basis, giving effect to the issuance of (i)&nbsp;10,874,756 shares in connection with sales from
our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">at-the-market</FONT></FONT> program between October&nbsp;1, 2020 and December&nbsp;31, 2020 and (ii)&nbsp;7,989,586 shares as a result of the conversion of $43&nbsp;million of our
Notes between October&nbsp;1, 2020 and December&nbsp;31, 2020; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on a pro forma as adjusted basis, giving effect to (i)&nbsp;the pro forma adjustments described above and
(ii)&nbsp;the issuance and sale of our common stock as contemplated by this prospectus supplement and our application of the net proceeds in the manner described in &#147;Use of Proceeds,&#148; after deducting the underwriting discounts and
commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">You should read the information in this table together with
&#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; in our Annual Report on Form&nbsp;10-K and our financial statements and the accompanying notes incorporated by reference in this prospectus
supplement and in the accompanying prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>September&nbsp;30,
2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Actual</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Pro&nbsp;Forma</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Pro&nbsp;Forma<BR>As&nbsp;Adjusted</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 178,700,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">303,225,979</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">158,535,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">158,535,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cash, cash equivalents and short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">337,236,178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">461,761,723</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term debt:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible senior notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,537,210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,139,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible bonds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,151,663</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,151,663</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total long-term debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,688,873</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,291,653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; equity:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C Preferred Stock, par value $0.001&nbsp;per share, 1,091 shares authorized and issued and
9 shares outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.001 par value, 600,000,000 shares authorized, 167,528,435 shares issued and
outstanding, actual, 186,392,777 shares issued and outstanding, pro forma, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares issued and outstanding, pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">186,392</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,205,842,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,361,072,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(881,858,432</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(877,184,236)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(247,834</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(247,834)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Inovio Pharmaceuticals, Inc. stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">323,903,846</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">483,826,612</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 377,592,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">502,118,265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The number of shares outstanding are based upon 167,528,435 shares of our common stock
outstanding as of September&nbsp;30, 2020, but excludes: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">9,290,347 shares issuable upon exercise of outstanding stock options pursuant to our stock incentive plans, at a
weighted average option exercise price of $6.66 per share as of September&nbsp;30, 2020; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,586,915 shares issuable upon vesting of service-based restricted stock units outstanding under our stock
incentive plans as of September&nbsp;30, 2020; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">663,353 shares issuable upon vesting of performance-based restricted stock units outstanding under our stock
incentive plans as of September&nbsp;30, 2020; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3,309 shares issuable upon the conversion of outstanding Series C Cumulative Convertible Preferred Stock as of
September&nbsp;30, 2020; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">11,039,574 shares issuable upon the conversion of the Notes outstanding as of September&nbsp;30, 2020, prior to
the conversion of $43&nbsp;million of Notes between October&nbsp;1, 2020 and December&nbsp;31, 2020 for 7,989,586 shares of common stock; and </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">shares that may become issuable upon the conversion of outstanding December 2019 Bonds. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc113891_10"></A>MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS OF OUR COMMON STOCK </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following summary describes the material U.S. federal
income tax consequences of the acquisition, ownership and disposition of our common stock acquired in this offering by <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders (as defined below). This discussion is not a complete analysis of all
potential U.S. federal income tax consequences relating thereto, and does not deal with foreign, state and local consequences that may be relevant to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders in light of their particular
circumstances, nor does it address U.S. federal tax consequences (such as gift and estate taxes) other than income taxes. Special rules different from those described below may apply to certain <FONT STYLE="white-space:nowrap">Non-U.S.</FONT>
Holders that are subject to special treatment under the Code, such as financial institutions, insurance companies, <FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations, broker-dealers and traders in securities, U.S. expatriates,
&#147;controlled foreign corporations,&#148; &#147;passive foreign investment companies,&#148; corporations that accumulate earnings to avoid U.S. federal income tax, corporations organized outside of the United States, any state thereof and the
District of Columbia that are nonetheless treated as U.S. taxpayers for U.S. federal income tax purposes, persons that hold our common stock as part of a &#147;straddle,&#148; &#147;hedge,&#148; &#147;conversion transaction,&#148; &#147;synthetic
security&#148; or integrated investment or other risk reduction strategy, persons who acquire our common stock through the exercise of an option or otherwise as compensation, persons subject to the alternative minimum tax or federal Medicare
contribution tax on net investment income, persons subject to special tax accounting rules under Section&nbsp;451(b) of the Code, &#147;qualified foreign pension funds&#148; as defined in Section&nbsp;897(l)(2) of the Code and entities all of the
interests of which are held by qualified foreign pension funds, partnerships and other pass-through entities or arrangements, and investors in such pass-through entities or arrangements. Such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders
are urged to consult their own tax advisors to determine the U.S. federal, state, local and other tax consequences that may be relevant to them. Furthermore, the discussion below is based upon the provisions of the Code, and Treasury Regulations,
rulings and judicial decisions thereunder as of the date hereof, and such authorities may be repealed, revoked or modified, perhaps retroactively, so as to result in U.S. federal income tax consequences different from those discussed below. We have
not requested a ruling from the U.S. Internal Revenue Service, or the IRS, with respect to the statements made and the conclusions reached in the following summary, and there can be no assurance that the IRS will agree with such statements and
conclusions. This discussion assumes that the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder holds our common stock as a &#147;capital asset&#148; within the meaning of Section&nbsp;1221 of the Code (generally, property held for
investment). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This discussion is for informational purposes only and is not tax advice. Persons considering the purchase of our common
stock pursuant to this offering should consult their own tax advisors concerning the U.S. federal income, estate and other tax consequences of acquiring, owning and disposing of our common stock in light of their particular situations as well as any
consequences arising under the laws of any other taxing jurisdiction, including any state, local or foreign tax consequences. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For the
purposes of this discussion, a <FONT STYLE="white-space:nowrap">&#147;Non-U.S.</FONT> Holder&#148; is, for U.S. federal income tax purposes, a beneficial owner of common stock that is neither a U.S. Holder, nor a partnership (or other entity treated
as a partnership for U.S. federal income tax purposes) regardless of its place of organization or formation. A &#147;U.S. Holder&#148; means a beneficial owner of common stock that is for U.S. federal income tax purposes any of the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an individual who is a citizen or resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation or other entity treated as a corporation for U.S. federal income tax purposes created or organized
in or under the laws of the United States, any state thereof or the District of Columbia; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an estate the income of which is subject to U.S. federal income taxation regardless of its source; or
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trust if it (1)&nbsp;is subject to the primary supervision of a court within the United States and one or more
U.S. persons have the authority to control all substantial decisions of the trust or (2)&nbsp;has a valid election in effect under applicable U.S. Treasury Regulations to be treated as a U.S. person. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Distributions </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Distributions, if any, made on our common stock to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder to the extent made out of our
current or accumulated earnings and profits (as determined under U.S. federal income tax principles) generally will constitute dividends for U.S. tax purposes and will be subject to withholding tax at a 30% rate or such lower rate as may be
specified by an applicable income tax treaty, subject to the discussions below regarding effectively connected income, backup withholding and foreign accounts. To obtain a reduced rate of withholding under a treaty, a
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder generally will be required to provide us with a properly executed IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> (in the case of individuals) or IRS Form
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (in the case of entities), or other appropriate form, certifying the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s entitlement to benefits
under that treaty. This certification must be provided to us or our paying agent prior to the payment of dividends and must be updated periodically. If a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is eligible for a reduced rate of U.S.
federal withholding tax under an income tax treaty and does not timely file the required certification, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder may be able to obtain a refund or credit of any excess amounts withheld by timely
filing an appropriate claim for a refund with the IRS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We generally are not required to withhold tax on dividends paid to a <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that are effectively connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the United States (and, if required by an applicable
income tax treaty, are attributable to a permanent establishment or fixed base that such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder maintains in the United States) if a properly executed IRS Form
<FONT STYLE="white-space:nowrap">W-8ECI,</FONT> stating that the dividends are so connected, is furnished to us (or, if stock is held through a financial institution or other agent, to such agent). In general, such effectively connected dividends
will be subject to U.S. federal income tax on a <FONT STYLE="white-space:nowrap">net-income</FONT> basis at the regular rates applicable to U.S. residents. A corporate <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder receiving effectively
connected dividends may also be subject to an additional &#147;branch profits tax,&#148; which is imposed, under certain circumstances, at a rate of 30% (or such lower rate as may be specified by an applicable income tax treaty) on the corporate <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s effectively connected earnings and profits, subject to certain adjustments. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors regarding any applicable
income tax treaties that may provide for different rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">To the extent distributions on our common stock, if any, exceed our current and
accumulated earnings and profits, they will first reduce the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s adjusted basis in our common stock, but not below zero, and then will be treated as gain to the extent of any excess amount
distributed, and taxed in the same manner as gain realized from a sale or other disposition of common stock as described in the next section. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Gain on
disposition of our common stock </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Subject to the discussions below regarding backup withholding and foreign accounts, a <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder generally will not be subject to U.S. federal income tax with respect to gain realized on a sale or other disposition of our common stock unless (a)&nbsp;the gain is effectively connected with a
trade or business of such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder in the United States (and, if required by an applicable income tax treaty, is attributable to a permanent establishment or fixed base that such holder maintains in the
United States), (b) the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is a nonresident alien individual and is present in the United States for 183 or more days in the taxable year of the disposition and certain other conditions are met or
(c)&nbsp;we are or have been a &#147;United States real property holding corporation&#148; within the meaning of Code Section&nbsp;897(c)(2) at any time within the shorter of the five-year period preceding such disposition or such <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s holding period. In general, we would be a United States real property holding corporation if our interests in U.S. real estate comprise (by fair market value) at least half of our business
assets. We believe that we have not been and we are not, and do not anticipate becoming, a United States real property holding corporation. Even if we are treated as a United States real property holding corporation, gain realized by a <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder on a disposition of our common stock will not be subject to U.S.&nbsp;federal income tax so long as (1)&nbsp;the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder owned, directly, indirectly
and constructively, no more than 5% of our common stock at all times within the shorter of (i)&nbsp;the five-year period preceding the disposition or (ii)&nbsp;the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s holding period and
(2)&nbsp;our common stock is regularly traded on an established securities market. There can be no assurance that our common stock will qualify or continue to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
qualify as regularly traded on an established securities market. If any gain on a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s disposition is taxable because we are a United
States real property holding corporation and the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s ownership of our common stock exceeds 5%, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will be taxed on such disposition
generally in the same manner as gain that is effectively connected with the conduct of a U.S. trade or business (subject to the provisions under an applicable income tax treaty), except that the branch profits tax generally will not apply. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder described in (a)&nbsp;above will be required to pay tax on the net gain derived from
the sale at regular U.S. federal income tax rates, and corporate <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders described in (a)&nbsp;above may be subject to the additional branch profits tax at a 30% rate or such lower rate as may be
specified by an applicable income tax treaty. Gain described in (b)&nbsp;above will be subject to U.S. federal income tax at a flat 30% rate or such lower rate as may be specified by an applicable income tax treaty, which gain may be offset by
certain <FONT STYLE="white-space:nowrap">U.S.-source</FONT> capital losses (even though the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is not considered a resident of the United States), provided that the
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder has timely filed U.S. federal income tax returns with respect to such losses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information
Reporting and Backup Withholding </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Generally, we must report information to the IRS with respect to any distributions we pay on our
common stock (even if the payments are exempt from withholding), including the amount of any such distributions, the name and address of the recipient and the amount, if any, of tax withheld. A similar report will be sent to the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder to whom any such distributions are paid. Pursuant to tax treaties or certain other agreements, the IRS may make its reports available to tax authorities in the recipient&#146;s country of residence.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Dividends paid by us (or our paying agents) to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder may also be subject to U.S.
backup withholding (currently at a rate of 24%). U.S. backup withholding generally will not apply to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder who provides a properly executed IRS Form <FONT STYLE="white-space:nowrap">W-8BEN,</FONT>
IRS Form <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> or IRS Form <FONT STYLE="white-space:nowrap">W-ECI</FONT> (as applicable), or otherwise establishes an exemption. Notwithstanding the foregoing, backup
withholding may apply if the payer has actual knowledge, or reason to know, that the holder is a U.S. person who is not an exempt recipient. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">U.S. information reporting and backup withholding requirements generally will apply to the proceeds of a disposition of our common stock
effected by or through a U.S. office of any broker, U.S. or foreign, except that information reporting and backup witholding requirements may be avoided if the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder provides a properly executed IRS
Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or IRS Form <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> or otherwise meets documentary evidence requirements for establishing <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> person status or otherwise establishes an exemption. Generally, U.S.&nbsp;information reporting and backup withholding requirements will not apply to a payment of disposition proceeds to a <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder where the transaction is effected outside the United States through a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> broker. Information
reporting and backup withholding requirements, however, may apply to a payment of disposition proceeds if the broker has actual knowledge, or reason to know, that the holder is, in fact, a U.S. person. For information reporting purposes, certain
brokers with substantial U.S. ownership or operations generally will be treated in a manner similar to U.S. brokers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Backup withholding
is not an additional tax. Any amounts withheld under the backup withholding rules may be credited against the tax liability of persons subject to backup withholding, provided that the required information is timely furnished to the IRS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Foreign accounts </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Sections 1471 through
1474 of the Code (commonly referred to as FATCA) impose a U.S. federal withholding tax of 30% on certain payments to a foreign financial institution (as specifically defined by applicable rules) unless such institution enters into an agreement with
the U.S. government to withhold on certain payments and to collect and provide to the U.S. tax authorities substantial information regarding U.S. account holders of such institution (which includes certain equity holders of such institution, as well
as certain account </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
holders that are foreign entities with U.S. owners). FATCA also generally imposes a federal withholding tax of 30% on certain payments to a <FONT STYLE="white-space:nowrap">non-financial</FONT>
foreign entity unless such entity provides the withholding agent with either a certification that it does not have any substantial direct or indirect U.S. owners or provides information regarding substantial direct and indirect U.S. owners of the
entity. An intergovernmental agreement between the United States and an applicable foreign country may modify those requirements. The withholding tax described above will not apply if the foreign financial institution or <FONT
STYLE="white-space:nowrap">non-financial</FONT> foreign entity otherwise qualifies for an exemption from the rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The withholding
provisions described above currently apply to payments of dividends. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The U.S. Treasury Department has released proposed regulations
which, if finalized in their present form, would eliminate the federal withholding tax of 30% that otherwise would apply to the gross proceeds of a disposition of our common stock. In its preamble to such proposed regulations, the U.S. Treasury
Department stated that taxpayers (including withholding agents) may generally rely on the proposed regulations until final regulations are issued. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders are encouraged to consult with their own tax
advisors regarding the possible implications of FATCA on their investment in our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>EACH PROSPECTIVE INVESTOR SHOULD
CONSULT ITS OWN TAX ADVISOR REGARDING THE TAX CONSEQUENCES OF PURCHASING, HOLDING AND DISPOSING OF OUR COMMON STOCK, INCLUDING THE CONSEQUENCES OF ANY RECENT OR PROPOSED CHANGE IN APPLICABLE LAW. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc113891_11"></A><A NAME="suppcov113891_3"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">BofA Securities, Inc. and Jefferies LLC are acting as representatives of each of the underwriters named below. Subject to the terms and
conditions set forth in an underwriting agreement among us and the underwriters, we have agreed to sell to the underwriters, and each of the underwriters has agreed, severally and not jointly, to purchase from us, the number of shares of common
stock set forth opposite its name below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>Underwriter</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number&nbsp;of<BR>Shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.15em; text-indent:-5.15em; font-size:10pt; font-family:Times New Roman">BofA Securities, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jefferies LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cantor Fitzgerald&nbsp;&amp; Co.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Oppenheimer&nbsp;&amp; Co. Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.15em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Subject to the terms and conditions set forth in the underwriting agreement, the underwriters have agreed,
severally and not jointly, to purchase all of the shares sold under the underwriting agreement if any of these shares are purchased. If an underwriter defaults, the underwriting agreement provides that the purchase commitments of the <FONT
STYLE="white-space:nowrap">non-defaulting</FONT> underwriters may be increased or the underwriting agreement may be terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have
agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act, or to contribute to payments the underwriters may be required to make in respect of those liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The underwriters are offering the shares, subject to prior sale, when, as and if issued to and accepted by them, subject to approval of legal
matters by their counsel, including the validity of the shares, and other conditions contained in the underwriting agreement, such as the receipt by the underwriters of officer&#146;s certificates and legal opinions. The underwriters reserve the
right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commissions and Discounts </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The representatives have advised us that the underwriters propose initially to offer the shares to the public at the public offering price set
forth on the cover page of this prospectus supplement and to dealers at that price less a concession not in excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. After the initial
offering, the public offering price, concession or any other term of the offering may be changed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table shows the public
offering price, underwriting discount and proceeds before expenses to us. The information assumes either no exercise or full exercise by the underwriters of their option to purchase additional shares. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85.5%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Per&nbsp;Share</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Without&nbsp;Option</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>With&nbsp;Option</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The expenses of the offering, not including the underwriting discount, are estimated at
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and are payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Option to Purchase Additional
Shares </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have granted an option to the underwriters, exercisable for 30 days after the date of this prospectus supplement, to
purchase up to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional shares of our common stock at the public offering price, less </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the underwriting discount. If the underwriters exercise this option, each will be obligated, subject to conditions contained in the underwriting agreement, to purchase a number of additional
shares proportionate to that underwriter&#146;s initial amount reflected in the above table. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Sales of Similar Securities </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We, our executive officers and directors have agreed not to sell or transfer any common stock or securities convertible into, exchangeable
for, exercisable for, or repayable with common stock, for 90 days after the date of this prospectus supplement without first obtaining the written consent of BofA Securities, Inc. and Jefferies LLC. Specifically, we and these other persons have
agreed, with certain limited exceptions, not to directly or indirectly </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">offer, pledge, sell or contract to sell any common stock, </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sell any option or contract to purchase any common stock, </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">purchase any option or contract to sell any common stock, </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">grant any option, right or warrant for the sale of any common stock, </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">lend or otherwise dispose of or transfer any common stock, </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">request or demand that we file or make a confidential submission of a registration statement related to the
common stock, or </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into any swap or other agreement that transfers, in whole or in part, the economic consequence of ownership
of any common stock whether any such swap or transaction is to be settled by delivery of shares or other securities, in cash or otherwise. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This <FONT STYLE="white-space:nowrap">lock-up</FONT> provision applies to common stock and to securities convertible into or exchangeable or
exercisable for or repayable with common stock. It also applies to common stock owned now or acquired later by the person executing the agreement or for which the person executing the agreement later acquires the power of disposition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Nasdaq Global Select Market Listing </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on The Nasdaq Global Select Market under the symbol &#147;INO.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Price Stabilization and Short Positions </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Until the distribution of the shares is completed, SEC rules may limit underwriters and selling group members from bidding for and purchasing
our common stock. However, the representatives may engage in transactions that stabilize the price of the common stock, such as bids or purchases to peg, fix or maintain that price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In connection with the offering, the underwriters may purchase and sell our common stock in the open market. These transactions may include
short sales, purchases on the open market to cover positions created by short sales and stabilizing transactions. Short sales involve the sale by the underwriters of a greater number of shares than they are required to purchase in the offering.
&#147;Covered&#148; short sales are sales made in an amount not greater than the underwriters&#146; option to purchase additional shares described above. The underwriters may close out any covered short position by either exercising their option to
purchase additional shares or purchasing shares in the open market. In determining the source of shares to close out the covered short position, the underwriters </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which they may purchase shares through the option granted to them.
&#147;Naked&#148; short sales are sales in excess of such option. The underwriters must close out any naked short position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriters are concerned
that there may be downward pressure on the price of our common stock in the open market after pricing that could adversely affect investors who purchase in the offering. Stabilizing transactions consist of various bids for or purchases of shares of
common stock made by the underwriters in the open market prior to the completion of the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Similar to other purchase transactions,
the underwriters&#146; purchases to cover the syndicate short sales may have the effect of raising or maintaining the market price of our common stock or preventing or retarding a decline in the market price of our common stock. As a result, the
price of our common stock may be higher than the price that might otherwise exist in the open market. The underwriters may conduct these transactions on The Nasdaq Global Select Market, in the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Neither we nor any of the underwriters make any
representation or prediction as to the direction or magnitude of any effect that the transactions described above may have on the price of our common stock. In addition, neither we nor any of the underwriters make any representation that the
representatives will engage in these transactions or that these transactions, once commenced, will not be discontinued without notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Passive Market
Making </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In connection with this offering, underwriters and selling group members may engage in passive market making transactions in
the common stock on The Nasdaq Global Market in accordance with Rule 103 of Regulation M under the Exchange Act during a period before the commencement of offers or sales of common stock and extending through the completion of distribution. A
passive market maker must display its bid at a price not in excess of the highest independent bid of that security. However, if all independent bids are lowered below the passive market maker&#146;s bid, that bid must then be lowered when specified
purchase limits are exceeded. Passive market making may cause the price of our common stock to be higher than the price that otherwise would exist in the open market in the absence of those transactions. The underwriters and dealers are not required
to engage in passive market making and may end passive market making activities at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Electronic Distribution </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In connection with the offering, certain of the underwriters or securities dealers may distribute prospectuses by electronic means, such as <FONT
STYLE="white-space:nowrap">e-mail.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Relationships </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Some of the underwriters and their affiliates have engaged in, and may in the future engage in, investment banking and other commercial
dealings in the ordinary course of business with us or our affiliates. They have received, or may in the future receive, customary fees and commissions for these transactions.<B><SUP STYLE="font-size:85%; vertical-align:top"> </SUP></B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, in the ordinary course of their business activities, the underwriters and their affiliates may make or hold a broad array of
investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers. Such investments and securities activities
may involve securities and/or instruments of ours or our affiliates. The underwriters and their affiliates may also make investment recommendations and/or publish or express independent research views in respect of such securities or financial
instruments and may hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to
Prospective Investors in the European Economic Area and the United Kingdom </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In relation to each Member State of the European Economic
Area and the United Kingdom, or a Relevant State, no shares have been offered or will be offered pursuant to the offering to the public in that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Relevant State prior to the publication of a prospectus in relation to the shares which has been approved by the competent authority in that Relevant State or, where appropriate, approved in
another Relevant State and notified to the competent authority in that Relevant State, all in accordance with the Prospectus Regulation, except that offers of shares may be made to the public in that Relevant State at any time under the following
exemptions under the Prospectus Regulation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to any legal entity which is a qualified investor as defined under the Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to fewer than 150 natural or legal persons (other than qualified investors as defined under the Prospectus
Regulation), subject to obtaining the prior consent of representatives for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in any other circumstances falling within Article&nbsp;1(4) of the Prospectus Regulation, provided that no such
offer of shares shall require us or any representative to publish a prospectus pursuant to Article&nbsp;3 of the Prospectus Regulation or supplement a prospectus pursuant to Article&nbsp;23 of the Prospectus Regulation. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Each person in a Relevant State who initially acquires any shares or to whom any offer is made will be deemed to have represented,
acknowledged and agreed to and with us and the representatives that it is a qualified investor within the meaning of the Prospectus Regulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the case of any shares being offered to a financial intermediary as that term is used in Article&nbsp;5(1) of the Prospectus Regulation,
each such financial intermediary will be deemed to have represented, acknowledged and agreed that the shares acquired by it in the offer have not been acquired on a non-discretionary basis on behalf of, nor have they been acquired with a view to
their offer or resale to, persons in circumstances which may give rise to an offer to the public other than their offer or resale in a Relevant State to qualified investors, in circumstances in which the prior consent of the representatives has been
obtained to each such proposed offer or resale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We, the representatives and their affiliates will rely upon the truth and accuracy of the
foregoing representations, acknowledgements and agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For the purposes of this provision, the expression an &#147;offer to the
public&#148; in relation to any shares in any Relevant State means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to decide to purchase or
subscribe for any shares, and the expression &#147;Prospectus Regulation&#148; means Regulation (EU) 2017/1129. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">References to the
Prospectus Regulation includes, in relation to the UK, the Prospectus Regulation as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The above selling restriction is in addition to any other selling restrictions set out below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In connection with the offering, the underwriters are not acting for anyone other than us and will not be responsible to anyone other than us
for providing the protections afforded to their clients nor for providing advice in relation to the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in the
United Kingdom </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This document is for distribution only to persons who (i)&nbsp;have professional experience in matters relating to
investments falling within and who qualify as investment professionals within the meaning of Article&nbsp;19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended, or the Financial Promotion Order,
(ii)&nbsp;are persons falling within Article&nbsp;49(2)(a) to (d)&nbsp;(&#147;high net worth companies, unincorporated associations etc.&#148;) of the Financial Promotion Order, (iii) are outside the United Kingdom, or (iv)&nbsp;are persons to whom
an invitation or inducement to engage in investment activity (within the meaning of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Section&nbsp;21 of the Financial Services and Markets Act 2000, as amended, or the FSMA) in connection with the issue or sale of any securities may otherwise lawfully be communicated or caused to
be communicated, all such persons together being referred to as &#147;relevant persons.&#148; This document is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or
investment activity to which this document relates is available only to relevant persons and will be engaged in only with relevant persons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to
Prospective Investors in Switzerland </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The shares may not be publicly offered in Switzerland and will not be listed on the SIX Swiss
Exchange, or SIX, or on any other stock exchange or regulated trading facility in Switzerland. This document has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of
Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this document nor any other offering
or marketing material relating to the shares or the offering may be publicly distributed or otherwise made publicly available in Switzerland. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Neither this document nor any other offering or marketing material relating to the offering, our company or the shares have been or will be
filed with or approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of shares will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA, or FINMA, and the offer of
shares has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes, or CISA. The investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to
acquirers of shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in the Dubai International Financial Centre </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This prospectus supplement relates to an Exempt Offer in accordance with the Offered Securities Rules of the Dubai Financial Services
Authority, or DFSA. This prospectus supplement is intended for distribution only to persons of a type specified in the Offered Securities Rules of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA has no
responsibility for reviewing or verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus supplement nor taken steps to verify the information set forth herein and has no responsibility for the prospectus
supplement. The shares to which this prospectus supplement relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the shares offered should conduct their own due diligence on the shares. If you do not
understand the contents of this prospectus supplement you should consult an authorized financial advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Australia
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">No placement document, prospectus, product disclosure statement or other disclosure document has been lodged with the Australian
Securities and Investments Commission, or ASIC, in relation to the offering. This prospectus does not constitute a prospectus, product disclosure statement or other disclosure document under the Corporations Act 2001, or the Corporations Act, and
does not purport to include the information required for a prospectus, product disclosure statement or other disclosure document under the Corporations Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Any offer in Australia of the shares may only be made to persons, or the Exempt Investors, who are &#147;sophisticated investors&#148; (within
the meaning of section 708(8) of the Corporations Act), &#147;professional investors&#148; (within the meaning of section 708(11) of the Corporations Act) or otherwise pursuant to one or more exemptions contained in section 708 of the Corporations
Act so that it is lawful to offer the shares without disclosure to investors under Chapter 6D of the Corporations Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The shares applied for by Exempt Investors in Australia must not be offered for sale in
Australia in the period of 12 months after the date of allotment under the offering, except in circumstances where disclosure to investors under Chapter 6D of the Corporations Act would not be required pursuant to an exemption under section 708 of
the Corporations Act or otherwise or where the offer is pursuant to a disclosure document which complies with Chapter 6D of the Corporations Act. Any person acquiring shares must observe such Australian
<FONT STYLE="white-space:nowrap">on-sale</FONT> restrictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This prospectus contains general information only and does not take account
of the investment objectives, financial situation or particular needs of any particular person. It does not contain any securities recommendations or financial product advice. Before making an investment decision, investors need to consider whether
the information in this prospectus supplement is appropriate to their needs, objectives and circumstances, and, if necessary, seek expert advice on those matters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Hong Kong </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The shares have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (a)&nbsp;to
&#147;professional investors&#148; as defined in the Securities and Futures Ordinance (Cap.&nbsp;571) of Hong Kong and any rules made under that Ordinance; or (b)&nbsp;in other circumstances which do not result in the document being a
&#147;prospectus&#148; as defined in the Companies Ordinance (Cap. 32) of Hong Kong or which do not constitute an offer to the public within the meaning of that Ordinance. No advertisement, invitation or document relating to the shares has been or
may be issued or has been or may be in the possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if
permitted to do so under the securities laws of Hong Kong) other than with respect to securities which are or are intended to be disposed of only to persons outside Hong Kong or only to &#147;professional investors&#148; as defined in the Securities
and Futures Ordinance and any rules made under that Ordinance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Japan </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The shares have not been and will not be registered under the Financial Instruments and Exchange Law of Japan (Law No.&nbsp;25 of 1948, as
amended) and, accordingly, will not be offered or sold, directly or indirectly, in Japan, or for the benefit of any Japanese Person or to others for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Japan or
to any Japanese Person, except in compliance with all applicable laws, regulations and ministerial guidelines promulgated by relevant Japanese governmental or regulatory authorities in effect at the relevant time. For the purposes of this paragraph,
&#147;Japanese Person&#148; shall mean any person resident in Japan, including any corporation or other entity organized under the laws of Japan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Singapore </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, the shares were not offered or
sold or caused to be made the subject of an invitation for subscription or purchase and will not be offered or sold or caused to be made the subject of an invitation for subscription or purchase, and this prospectus supplement or any other document
or material in connection with the offer or sale, or invitation for subscription or purchase, of the shares, has not been circulated or distributed, nor will it be circulated or distributed, whether directly or indirectly, to any person in Singapore
other than (i)&nbsp;to an institutional investor (as defined in Section&nbsp;4A of the Securities and Futures Act (Chapter 289) of Singapore, as modified or amended from time to time, or the SFA) pursuant to Section&nbsp;274 of the SFA, (ii)&nbsp;to
a relevant person (as defined in Section&nbsp;275(2) of the SFA) pursuant to Section&nbsp;275(1) of the SFA, or any person pursuant to Section&nbsp;275(1A) of the SFA, and in accordance with the conditions specified in Section&nbsp;275 of the SFA,
or (iii)&nbsp;otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Where the shares are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant
person which is: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole
business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an
individual who is an accredited investor, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman">securities or securities-based derivatives contracts (each term as defined in
Section&nbsp;2(1) of the SFA) of that corporation or the beneficiaries&#146; rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the shares pursuant to
an offer made under Section&nbsp;275 of the SFA except: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to an institutional investor or to a relevant person, or to any person arising from an offer referred to in
Section&nbsp;275(1A) or Section&nbsp;276(4)(i)(B) of the SFA; </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman">where no consideration is or will be given for the
transfer; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman">where the transfer is by operation of law; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:12%; font-size:10pt; font-family:Times New Roman">as specified in Section&nbsp;276(7) of the SFA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Canada </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The shares may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in
National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> <I>Prospectus Exemptions</I> or subsection 73.3(1) of the <I>Securities Act</I> (Ontario), and are permitted clients, as defined in National Instrument
<FONT STYLE="white-space:nowrap">31-103</FONT> <I>Registration Requirements, Exemptions and Ongoing Registrant Obligations</I>. Any resale of the shares must be made in accordance with an exemption from, or in a transaction not subject to, the
prospectus requirements of applicable securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Securities legislation in certain provinces or territories of Canada may provide a
purchaser with remedies for rescission or damages if this prospectus supplement (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit
prescribed by the securities legislation of the purchaser&#146;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these
rights or consult with a legal advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to section 3A.3 (or, in the case of securities issued or guaranteed by the government of
a <FONT STYLE="white-space:nowrap">non-Canadian</FONT> jurisdiction, section 3A.4) of National Instrument <FONT STYLE="white-space:nowrap">33-105</FONT> <I>Underwriting Conflicts</I> (<B>NI <FONT STYLE="white-space:nowrap">33-105</FONT></B>), the
underwriters are not required to comply with the disclosure requirements of NI <FONT STYLE="white-space:nowrap">33-105</FONT> regarding underwriter conflicts of interest in connection with this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Israel </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This document does not constitute a prospectus under the Israeli Securities Law, 5728-1968, or the Securities Law, and has not been filed with
or approved by the Israel Securities Authority. In the State of Israel, this document is being distributed only to, and is directed only at, and any offer of the shares is directed only at, investors listed in the first addendum, or the Addendum, to
the Israeli Securities Law, consisting primarily of joint investment in trust funds, provident funds, insurance companies, banks, portfolio managers, investment advisors, members of the Tel Aviv Stock Exchange, underwriters, venture capital funds,
entities with equity in excess of NIS 50&nbsp;million and &#147;qualified individuals&#148;, each as defined in the Addendum (as it may be amended from time to time), collectively referred to as qualified investors (in each case purchasing for their
own account or, where permitted under the Addendum, for the accounts of their clients who are investors listed in the Addendum). Qualified investors will be required to submit written confirmation that they fall within the scope of the Addendum, are
aware of the meaning of same and agree to it. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc113891_12"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Certain legal matters will be passed upon for us by Cooley LLP, Reston, Virginia. The underwriters are being represented in connection with
this offering by Wilmer Cutler Pickering Hale and Dorr LLP, New York, New York. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc113891_13"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, has audited our consolidated financial statements included in our
Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2019, and the effectiveness of our internal control over financial reporting as of December&nbsp;31, 2019, as set forth in their reports, which
are incorporated by reference in this prospectus supplement and elsewhere in the registration statement. Our financial statements are incorporated by reference in reliance on Ernst&nbsp;&amp; Young LLP&#146;s reports, given on their authority as
experts in accounting and auditing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc113891_14"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> with respect to the shares of common
stock offered hereby. This prospectus supplement, which constitutes part of the registration statement, does not contain all the information set forth in the registration statement and its exhibits. For further information with respect to us and the
common stock offered by this prospectus supplement, we refer you to the registration statement and its exhibits. Statements contained in this prospectus supplement as to the contents of any contract or any other document referred to are not
necessarily complete, and in each instance, we refer you to the copy of the contract or other document filed as an exhibit to the registration statement. Each of these statements is qualified in all respects by this reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are currently subject to the information requirements of the Exchange Act, and in accordance therewith file periodic reports, proxy
statements and other information with the SEC. Some of this information may be accessed through the SEC&#146;s Internet address at <I>http://www.sec.gov</I>. We maintain a website at <I>http://www.inovio.com</I>. You may access our annual reports on
Form <FONT STYLE="white-space:nowrap">10-K,</FONT> quarterly reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> current reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> and amendments to those reports filed pursuant to Sections
13(a) or 15(d) of the Exchange Act with the SEC free of charge at our website as soon as reasonably practicable after such material is electronically filed with, or furnished to, the SEC. Except for the information incorporated by reference as noted
herein, our website and the information contained on that site, or connected to that site, are not incorporated into and are not a part of this prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc113891_15"></A>INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; into this prospectus supplement the information in documents we file with it, which
means that we can disclose important information to you by referring you to those documents. The information we incorporate by reference is considered to be a part of this prospectus supplement and accompanying prospectus, and information that we
file later with the SEC will automatically update and supersede this information. Any statement contained in any document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this
prospectus supplement and the accompanying prospectus to the extent that a statement contained in or omitted from this prospectus supplement or the accompanying prospectus, or in any other subsequently filed document that also is or is deemed to be
incorporated by reference herein, modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus supplement. We incorporate by
reference the documents or information listed below and any future filings we make with the SEC (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-14888)</FONT> under Sections 13(a), 13(c), 14, or 15(d) of the Exchange Act (in each case, other than
those documents or the portions of those documents not deemed to be filed) until the offering is completed: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1055726/000105572620000012/ino-12312019x10k.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the fiscal year ended December&nbsp;31, 2019, filed with the SEC on March&nbsp;12, 2020; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our <A HREF="http://www.sec.gov/Archives/edgar/data/1055726/000105572620000022/ino-2020xproxy.htm">definitive proxy
 statement</A> on Schedule 14A, filed with the SEC on March&nbsp;27, 2020 (other than information furnished rather than filed); </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the fiscal quarters ended
March&nbsp;31, 2020, June&nbsp;30, 2020 and September&nbsp;30, 2020 filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1055726/000105572620000032/ino-3312010q.htm">May<U></U>&nbsp;
11, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1055726/000105572620000048/ino-6302010q.htm">August<U></U>&nbsp;
10, 2020</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1055726/000105572620000052/ino-20200930.htm">November<U></U>&nbsp;9, 2020</A>, respectively; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed on <A HREF="http://www.sec.gov/Archives/edgar/data/1055726/000119312520000651/d863139d8k.htm">January
<U></U>&nbsp;2, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1055726/000119312520008085/d874165d8k.htm">January<U></U>&nbsp;
15, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1055726/000119312520028310/d858444d8k.htm">February<U></U>&nbsp;7, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1055726/000119312520065842/d891484d8k.htm">March<U></U>&nbsp;
9, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1055726/000119312520098305/d806992d8k.htm">April<U></U>&nbsp;3, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1055726/000119312520099003/d882866d8k.htm">April<U></U>&nbsp;
6, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1055726/000119312520140512/d901178d8k.htm">May<U></U>&nbsp;12, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1055726/000119312520145017/d919617d8k.htm">May<U></U>&nbsp;18,
2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1055726/000119312520159486/d937207d8k.htm">June<U></U>&nbsp;3, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1055726/000119312520179128/d924073d8k.htm">June<U></U>&nbsp;25,
2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1055726/000119312520239111/d96154d8k.htm">September<U></U>&nbsp;3, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1055726/000119312520256781/d939902d8k.htm">September<U></U>&nbsp;
28, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1055726/000119312520270257/d87487d8k.htm">October<U></U>&nbsp;15, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1055726/000119312520294751/d41811d8k.htm">November<U></U>&nbsp;
16, 2020</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1055726/000119312521000955/d26944d8k.htm">January<U></U>&nbsp;4, 2021</A>, to the extent the information in such reports is filed and not furnished; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Description of our common stock contained set forth in our registration statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1055726/000119312514340354/d787144d8a12b.htm">Form
 <FONT STYLE="white-space:nowrap">8-A</FONT></A>, filed with the SEC on September&nbsp;
12, 2014, including any amendments thereto or reports filed for the purposes of updating this description, including <A HREF="http://www.sec.gov/Archives/edgar/data/1055726/000105572620000012/ino-12312019x10xkex49.htm">Exhibit 4.9</A> to our Annual
Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2019, filed with the SEC on March&nbsp;12, 2020. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Notwithstanding the statements in the preceding paragraphs, no document, report or exhibit (or portion of any of the foregoing) or any other
information that we have &#147;furnished&#148; to the SEC pursuant to the Exchange Act shall be incorporated by reference into this prospectus supplement and the accompanying prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Copies of our reports on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> Forms <FONT STYLE="white-space:nowrap">10-Q,</FONT> Forms <FONT
STYLE="white-space:nowrap">8-K,</FONT> and amendments to those reports may also be obtained, free of charge, electronically through our investor relations website located at <I>http://www.inovio.com</I> as soon as reasonably practical after we file
such material with, or furnish it to, the SEC. The reference to our website does not constitute incorporation by reference of the information contained in our website. We do not consider information contained on, or that can be accessed through, our
website to be part of this prospectus or the related registration statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">You may request, and we will provide to you, a copy of these
filings at no cost by writing or telephoning us at the following address: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Inovio Pharmaceuticals, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">660 W. Germantown Pike, Suite 110 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Plymouth Meeting, Pennsylvania 19462 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attn: Investor Relations </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Phone:
(267) <FONT STYLE="white-space:nowrap">440-4200</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g110733g03v83.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may, from time to time,
offer to sell common stock in amounts, at prices and on terms described in one or more supplements to this prospectus. You should read this prospectus and any supplement carefully before you invest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus describes some of the general terms that may apply to an offering of our common stock. The specific terms and any other information relating
to a specific offering will be set forth in a post-effective amendment to the registration statement of which this prospectus is a part or in a supplement to this prospectus or may be set forth in one or more documents incorporated by reference in
this prospectus. The amendment or supplement, as applicable, may also add, update or change information contained in this prospectus with respect to that specific offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock may be offered and sold in the same offering or in separate offerings; to or through underwriters, dealers, and agents; or directly to
purchasers; or through a combination of these methods. The names of any underwriter, dealer or agents involved in the sale of our common stock and their compensation will be described in an applicable prospectus supplement. See &#147;Plan of
Distribution.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is listed on The Nasdaq Global Select Market under the symbol &#147;INO.&#148; On January&nbsp;19, 2021, the last
reported sale price for our common stock was $10.10. You are encouraged to obtain current market quotations for shares of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our principal
executive offices are located at 660 W. Germantown Pike, Suite 110, Plymouth Meeting, Pennsylvania 19462, and our telephone number at that address is (267) <FONT STYLE="white-space:nowrap">440-4200.</FONT> </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Investing in our common stock involves a high degree of risk. See &#147;<A HREF="#rom110733_2">Risk Factors</A>&#148; on page&nbsp;3 of this prospectus.
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved these securities or determined if
this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus is
January&nbsp;20, 2021. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom110733_1">INOVIO PHARMACEUTICALS, INC.</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom110733_2">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom110733_3">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom110733_4">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom110733_5">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom110733_6">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom110733_7">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom110733_8">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom110733_9">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> that we filed with the Securities and Exchange
Commission, or the SEC, using the &#147;shelf&#148; registration process as a &#147;well-known seasoned issuer,&#148; as defined in Rule 405 under the Securities Act of 1933, as amended, or the Securities Act. By using a shelf registration
statement, we may offer and sell from time to time in one or more offerings the common stock described in this prospectus. No limit exists on the aggregate number of shares of common stock we may sell pursuant to the registration statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus provides you with a general description of our common stock. Each time we sell shares of our common stock, we will provide a prospectus
supplement that will contain specific information about the terms of that offering. The prospectus supplement, or information incorporated by reference in this prospectus or any prospectus supplement that is of a more recent date, may also add,
update or change information contained in this prospectus. To the extent that any statement that we make in a prospectus supplement is inconsistent with statements made in this prospectus, the statements made in this prospectus will be deemed
modified or superseded by those made in the prospectus supplement. You should read both this prospectus and any applicable prospectus supplement, together with the additional information described below under the heading &#147;Where You Can Find
More Information&#148;. This prospectus may not be used to consummate a sale of our common stock unless it is accompanied by a prospectus supplement. We may also authorize one or more free writing prospectuses to be provided to you that may contain
material information relating to an offering of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not authorized anyone to provide you with information other than the
information contained or incorporated by reference in this prospectus and any related prospectus supplement, or in any free writing prospectus that we may authorize in connection with an offering of our shares of common stock. No one is making
offers to sell or seeking offers to buy shares of our common stock in any jurisdiction where the offer or sale is not permitted. You should assume that the information contained in this prospectus and any prospectus supplement is accurate only as of
the date on the front of this prospectus or the prospectus supplement, as applicable, and that any information we have incorporated by reference in this prospectus or any prospectus supplement is accurate only as of the date given in the document
incorporated by reference, regardless of the time of delivery of this prospectus, any applicable prospectus supplement or any sale of our common stock. Our business, financial condition, results of operations and prospects may have changed since
that date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">References in this prospectus to &#147;Inovio,&#148; the &#147;Company,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to
Inovio Pharmaceuticals, Inc., together with our consolidated subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have proprietary rights to a number of trademarks used in this prospectus
which are important to our business, including SynCon<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, CELLECTRA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and the Inovio logo. Solely for convenience, the trademarks and
trade names in this prospectus are referred to without the <SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and TM symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the
fullest extent under applicable law, their rights thereto. All other brand names or trademarks appearing in this prospectus are the property of their respective holders. Use or display by us of other parties&#146; trademarks, trade dress, or
products in this prospectus is not intended to, and does not, imply a relationship with, or endorsements or sponsorship of, us by the trademark or trade dress owners. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom110733_1"></A>Inovio Pharmaceuticals, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases
associated with human papillomavirus, or HPV, cancer, and infectious diseases. Our DNA medicine pipeline is composed of three types of product candidates, DNA vaccines, DNA immunotherapies and DNA encoded monoclonal antibodies. In clinical trials,
we have demonstrated that a DNA medicine can be delivered directly into cells in the body via our proprietary smart device to consistently activate robust and fully functional T cell and antibody responses against targeted cancers and pathogens.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our novel DNA medicine candidates are made using our proprietary SynCon technology that creates optimized plasmids, which are circular strands of DNA
that can produce antigens independently inside a cell to help the person&#146;s immune system recognize and destroy cancerous or virally infected cells. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our hand-held CELLECTRA smart delivery devices provide optimized uptake of our DNA medicines within the cell, overcoming a key limitation of other <FONT
STYLE="white-space:nowrap">DNA-based</FONT> technology approaches. Human data to date have shown a favorable tolerability profile of our DNA medicines delivered directly into cells in the body using the CELLECTRA smart delivery device in more than
7,000 administrations across approximately 2,500 patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our corporate strategy is to advance, protect, and provide our novel DNA medicines to meet
urgent and emerging global health needs. We continue to advance and validate an array of DNA medicine candidates that target <FONT STYLE="white-space:nowrap">COVID-19,</FONT> <FONT STYLE="white-space:nowrap">HPV-related</FONT> diseases, cancer, and
infectious diseases. We aim to advance these candidates through commercialization and continue to leverage third-party resources through collaborations and partnerships, including product license agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine, The Bill&nbsp;&amp; Melinda Gates Foundation, Coalition for Epidemic
Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, GeneOne Life Science, HIV Vaccines Trial Network, the U.S. Defense Threat Reduction Agency&#146;s Medical CBRN Defense Consortium, International
Vaccine Institute, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals,
Thermo Fisher Scientific, Richter-Helm BioLogics, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We or our collaborators are currently conducting or planning clinical studies of our DNA medicines for <FONT STYLE="white-space:nowrap">HPV-associated</FONT>
precancers, including cervical, vulvar, and anal dysplasia; <FONT STYLE="white-space:nowrap">HPV-associated</FONT> cancers, including head&nbsp;&amp; neck, cervical, anal, penile, vulvar, and vaginal; other
<FONT STYLE="white-space:nowrap">HPV-associated</FONT> disorders, such as recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome; Lassa fever; Zika virus; and the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> virus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All of our product candidates are in the research and development phase. We have not generated any
revenues from the sale of any products, and we do not expect to generate any such revenues for at least the next several years. We earn revenue from license fees and milestone revenue and collaborative research and development agreements. Our
product candidates will require significant additional research and development efforts, including extensive preclinical and clinical testing. All product candidates that we advance to clinical testing will require regulatory approval prior to
commercial use and will require significant costs for commercialization. We may not be successful in our research and development efforts, and we may never generate sufficient product revenue to be profitable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We were incorporated under the laws of the State of Delaware in June 2001. Our principal executive offices
are located at 660 W. Germantown Pike, Suite 110, Plymouth Meeting, Pennsylvania 19462. Our telephone number is (267) <FONT STYLE="white-space:nowrap">440-4200.</FONT> Our common stock is listed on the Nasdaq Global Select Market under the symbol
&#147;INO.&#148; Our internet website address is www.inovio.com. The information contained on our website is not incorporated by reference into this prospectus, and you should not consider any information contained on, or that can be accessed
through, our website as part of this prospectus or in deciding whether to purchase our securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom110733_2"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investing in our securities involves a high degree of risk. Before deciding whether to invest in our securities, you should consider carefully the risks and
uncertainties described under the heading &#147;Risk Factors&#148; contained in the applicable prospectus supplement and any related free writing prospectus, and discussed under the section entitled &#147;Risk Factors&#148; contained in our most
recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and in our most recent Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> as well as any amendments thereto reflected in subsequent filings with the SEC,
which are incorporated by reference into this prospectus in their entirety, together with other information in this prospectus, the documents incorporated by reference and any free writing prospectus that we may authorize for use in connection with
this offering. The risks described in these documents are not the only ones we face, but those that we consider to be material. There may be other unknown or unpredictable economic, business, competitive, regulatory or other factors that could have
material adverse effects on our future results. Past financial performance may not be a reliable indicator of future performance, and historical trends should not be used to anticipate results or trends in future periods. If any of these risks
actually occurs, our business, financial condition, results of operations or cash flow could be seriously harmed. This could cause the trading price of our common stock to decline, resulting in a loss of all or part of your investment. Please also
read carefully the section below entitled &#147;Special Note Regarding Forward-Looking Statements.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom110733_3"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus, and the documents incorporated in this prospectus by reference, contain forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. These statements are based on our management&#146;s current beliefs, expectations and assumptions about future events, conditions and results and on information currently available to us. Discussions
containing these forward-looking statements may be found, among other places, in the sections titled &#147;Business,&#148; &#147;Risk Factors&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations&#148; incorporated by reference from our most recent Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K&nbsp;and</FONT> our most recent Quarterly Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q&nbsp;filed</FONT>
with the SEC, as well as any amendments thereto reflected in subsequent filings with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus contains, and the documents incorporated by
reference herein and any applicable prospectus supplement may contain, forward-looking statements within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended, or the Securities Act, and Section&nbsp;21E of the Securities
Exchange Act of 1934, as amended, or the Exchange Act. These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors which may cause our actual results,
performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Forward-looking statements may include, but are not limited to statements about:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our history of losses; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our lack of products that have received regulatory approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">uncertainties inherent in clinical trials and product development programs, including but not limited to the fact
that <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical results may not be indicative of results achievable in other trials or for other indications, that results from one study may not necessarily be reflected or supported by the
results of other similar studies, that results from an animal study may not be indicative of results achievable in human studies, that clinical testing is expensive and can take many years to complete, that the outcome of any clinical trial is
uncertain and failure can occur at any time during the clinical trial process, and that our electroporation technology and DNA vaccines may fail to show the desired safety and efficacy traits in clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of funding; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to manufacture vaccine candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish or maintain collaborations, licensing or other arrangements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability or potential availability of alternative therapies or treatments for the conditions we or our
collaborators target, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that we and our collaborators hope to develop; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether our proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of
others or can withstand claims of invalidity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of government healthcare legislation and proposals; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our use of the proceeds from any offerings under this prospectus. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In some cases, you can identify forward-looking statements by terms such as &#147;anticipate,&#148; &#147;believe,&#148; &#147;continue,&#148;
&#147;could,&#148; &#147;estimate,&#148; &#147;expects,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;might,&#148; &#147;plan,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;project,&#148; &#147;should,&#148; &#147;will,&#148;
&#147;would&#148; or the negative or plural of those terms, and similar expressions intended to identify statements about the future, although not all forward-looking statements contain these words. These statements involve known and unknown risks,
uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In addition, statements that
&#147;we believe&#148; and similar statements reflect our beliefs </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and opinions on the relevant subject. These statements are based upon information available to us as of the date of this prospectus, and while we believe such information forms a reasonable basis
for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements
are inherently uncertain and investors are cautioned not to unduly rely upon these statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should read this prospectus, the registration
statement of which this prospectus is a part, the documents incorporated by reference herein, and any applicable prospectus supplement completely and with the understanding that our actual future results may be materially different from what we
expect. Given these risks, uncertainties and other factors, many of which are beyond our control, we cannot assure you that the forward-looking statements will prove to be accurate, and you should not place undue reliance on these forward-looking
statements. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a
representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as
required by law, we assume no obligation to update these forward-looking statements publicly, or to revise any forward-looking statements to reflect events or developments occurring after the date of this prospectus supplement, even if new
information becomes available in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom110733_4"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will retain broad discretion over the use of the net proceeds from the sale of our common stock offered under this prospectus. Unless we indicate otherwise
in the applicable prospectus supplement, we anticipate that any net proceeds will be used for working capital and general corporate purposes. We will set forth in the applicable prospectus supplement our intended use for the net proceeds received
from the sale of any common stock sold pursuant to that prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom110733_5"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may sell the common stock to one or more underwriters for public offering and sale by them and may also sell the common stock to investors directly or
through agents. We will name any underwriter or agent involved in the offer and sale of common stock in the applicable prospectus supplement. We have reserved the right to sell or exchange our common stock directly to investors on our own behalf in
those jurisdictions where we are authorized to do so. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may distribute the common stock from time to time in one or more transactions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at a fixed price or prices, which may be changed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at market prices prevailing at the time of sale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at prices related to such prevailing market prices; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at negotiated prices. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may also, from time to time, authorize dealers, acting as our agents, to offer and sell the common stock upon the terms and conditions set forth in the
applicable prospectus supplement. We, or the purchasers of the common stock for whom the underwriters may act as agents, may compensate underwriters in the form of underwriting discounts or commissions, in connection with the sale of the common
stock. Underwriters may sell the common stock to or through dealers, and those dealers may receive compensation in the form of discounts, concessions or commissions from the underwriters and/or commissions from the purchasers for whom they may act
as agent. Unless otherwise indicated in the applicable prospectus supplement, an agent will be acting on a best efforts basis and a dealer will purchase the common stock as a principal and may then resell the common stock at varying prices to be
determined by the dealer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will describe in the applicable prospectus supplement any compensation we pay to underwriters or agents in connection with
the offering of our common stock, and any discounts, concessions or commissions allowed by underwriters to participating dealers. Dealers and agents participating in the distribution of the common stock may be deemed to be underwriters, and any
discounts and commissions received by them and any profit realized by them on resale of the common stock may be deemed to be underwriting discounts and commissions. We may enter into agreements to indemnify underwriters, dealers and agents against
certain civil liabilities, including liabilities under the Securities Act and to reimburse these persons for certain expenses. We may grant underwriters who participate in the distribution of the common stock we are offering under this prospectus an
option to purchase additional shares in connection with the distribution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To facilitate the offering of our common stock, certain persons participating
in the offering may engage in transactions that stabilize, maintain, or otherwise affect the price of the common stock. This may include over-allotments or short sales of the common stock, which involve the sale by persons participating in the
offering of more common stock than we sold to them. In these circumstances, these persons would cover such over-allotments or short positions by making purchases in the open market or by exercising their option to purchase additional shares, if any.
In addition, these persons may stabilize or maintain the price of the common stock by bidding for or purchasing common stock in the open market or by imposing penalty bids, whereby selling concessions allowed to dealers participating in the offering
may be reclaimed if the common stock sold by them is repurchased in connection with stabilization transactions. The effect of these transactions may be to stabilize or maintain the market price of the common stock at a level above that which might
otherwise prevail in the open market. These transactions may be discontinued at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may indemnify the underwriters, agents or dealers who
participate in the distribution of our common stock against certain liabilities, including liabilities under the Securities Act. We may also contribute to payments that the underwriters, dealers or agents or any of their controlling persons may be
required to make in respect of such liabilities. Certain underwriters, dealers or agents and their associates may engage in transactions with and perform services for us in the ordinary course of our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom110733_6"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated in the applicable prospectus supplement, certain legal matters in connection with the offering and the validity of the securities
offered by this prospectus, and any supplement thereto, will be passed upon by Cooley LLP, Reston, Virginia. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom110733_7"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, has audited our consolidated financial statements included in our Annual Report on <FONT
STYLE="white-space:nowrap">Form&nbsp;10-K&nbsp;for</FONT> the year ended December&nbsp;31, 2019, and the effectiveness of our internal control over financial reporting as of December&nbsp;31, 2019, as set forth in their reports, which are
incorporated by reference in this prospectus and elsewhere in the registration statement. Our financial statements are incorporated by reference in reliance on Ernst&nbsp;&amp; Young LLP&#146;s reports, given on their authority as experts in
accounting and auditing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom110733_8"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus and any prospectus supplement are part of the registration statement
<FONT STYLE="white-space:nowrap">on&nbsp;Form&nbsp;S-3&nbsp;we&nbsp;filed</FONT> with the SEC under the Securities Act and do not contain all the information set forth or incorporated by reference in the registration statement. Whenever a reference
is made in this prospectus or any prospectus supplement to any of our contracts, agreements or other documents, the reference may not be complete and you should refer to the exhibits that are a part of the registration statement or the exhibits to
the reports or other documents incorporated by reference into this prospectus or prospectus supplement for a copy of such contract, agreement or other document. Because we are subject to the information and reporting requirements of the Exchange
Act, we file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the Internet at the SEC&#146;s website at <I>http://www.sec.gov</I>. Our Annual Report <FONT
STYLE="white-space:nowrap">on&nbsp;Form&nbsp;10-K,&nbsp;Quarterly&nbsp;Reports</FONT> <FONT STYLE="white-space:nowrap">on&nbsp;Form&nbsp;10-Q&nbsp;and&nbsp;Current</FONT> Reports
<FONT STYLE="white-space:nowrap">on&nbsp;Form&nbsp;8-K,&nbsp;including&nbsp;any</FONT> amendments to those reports, and other information that we file with or furnish to the SEC pursuant to Section&nbsp;13(a) or 15(d) of the Exchange Act can also be
accessed free of charge on the Investor section of our website, which is located at <I>http://www.inovio.com</I>. These filings will be available as soon as reasonably practicable after we electronically file such material with, or furnish it to,
the SEC. Information contained on or accessible through our website is not a part of this prospectus and is not incorporated by reference herein, and the inclusion of our website address in this prospectus is an inactive textual reference only. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom110733_9"></A>INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; the information we file with it, which means that we can disclose important information to you by
referring to those documents. The information incorporated by reference is an important part of this prospectus, and information that we file later with the SEC will automatically update and supersede this information. We incorporate by reference
the following documents we filed with the SEC pursuant to Section&nbsp;13 of the Exchange Act and any future filings we will make with the SEC (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-14888)</FONT> under Sections 13(a), 13(c), 14, or
15(d) of the Exchange Act after the date of this prospectus until the termination of the offering of the shares covered by this prospectus (in each case, other than those documents or the portions of those documents not deemed to be filed): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1055726/000105572620000012/ino-12312019x10k.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the fiscal year ended December&nbsp;31, 2019, filed with the SEC on March&nbsp;12, 2020; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our <A HREF="http://www.sec.gov/Archives/edgar/data/1055726/000105572620000022/ino-2020xproxy.htm">definitive proxy
 statement</A> on Schedule 14A, filed with the SEC on March&nbsp;27, 2020 (other than information furnished rather than filed); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the fiscal quarters ended
March&nbsp;31, 2020, June&nbsp;30, 2020 and September&nbsp;30, 2020 filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1055726/000105572620000032/ino-3312010q.htm">May&nbsp;
11, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1055726/000105572620000048/ino-6302010q.htm">August&nbsp;10, 2020</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1055726/000105572620000052/ino-20200930.htm">November&nbsp;9,
2020</A>, respectively; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed on <A HREF="http://www.sec.gov/Archives/edgar/data/1055726/000119312520000651/d863139d8k.htm">January&nbsp;2,
 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1055726/000119312520008085/d874165d8k.htm">January&nbsp;15, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1055726/000119312520028310/d858444d8k.htm">February&nbsp;
7, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1055726/000119312520065842/d891484d8k.htm">March&nbsp;9, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1055726/000119312520098305/d806992d8k.htm">April&nbsp;
3, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1055726/000119312520099003/d882866d8k.htm">April&nbsp;6, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1055726/000119312520140512/d901178d8k.htm">May&nbsp;
12, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1055726/000119312520145017/d919617d8k.htm">May&nbsp;18, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1055726/000119312520159486/d937207d8k.htm">June&nbsp;
3, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1055726/000119312520179128/d924073d8k.htm">June&nbsp;25, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1055726/000119312520239111/d96154d8k.htm">September&nbsp;
3, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1055726/000119312520256781/d939902d8k.htm">September&nbsp;28, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1055726/000119312520270257/d87487d8k.htm">October&nbsp;
15, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1055726/000119312520294751/d41811d8k.htm">November&nbsp;16, 2020</A> and<A HREF="http://www.sec.gov/Archives/edgar/data/1055726/000119312521000955/d26944d8k.htm"> January&nbsp;4, 2021</A>,
to the extent the information in such reports is filed and not furnished; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Description of our common stock contained set forth in our registration statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1055726/000119312514340354/d787144d8a12b.htm">Form
 <FONT STYLE="white-space:nowrap">8-A</FONT></A>, filed with the SEC on September&nbsp;
12, 2014, including any amendments thereto or reports filed for the purposes of updating this description, including <A HREF="http://www.sec.gov/Archives/edgar/data/1055726/000105572620000012/ino-12312019x10xkex49.htm">Exhibit 4.9</A> to our Annual
Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2019, filed with the SEC on March&nbsp;12, 2020. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the statements in the preceding paragraphs, no document, report or exhibit (or portion of any of the foregoing) or any other information that
we have &#147;furnished&#148; to the SEC pursuant to the Exchange Act shall be incorporated by reference into this prospectus supplement and the accompanying prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Copies of our reports on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> Forms <FONT STYLE="white-space:nowrap">10-Q,</FONT> Forms <FONT
STYLE="white-space:nowrap">8-K,</FONT> and amendments to those reports may also be obtained, free of charge, electronically through our investor relations website located at <I>http://www.inovio.com</I> as soon as reasonably practical after we file
such material with, or furnish it to, the SEC. The reference to our website does not constitute incorporation by reference of the information contained in our website. We do not consider information contained on, or that can be accessed through, our
website to be part of this prospectus or the related registration statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may request, and we will provide to you, a copy of these filings at no
cost by writing or telephoning us at the following address: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Inovio Pharmaceuticals, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">660 W. Germantown Pike, Suite 110 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Plymouth Meeting, Pennsylvania 19462 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attn: Investor Relations </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Phone:
(267) <FONT STYLE="white-space:nowrap">440-4200</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g113891g94r84.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>$150,000,000 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:42%">&nbsp;</P></center>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS SUPPLEMENT </B></P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:42%">&nbsp;</P></center> <P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Joint
Book-Running Managers </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:18pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:18pt">
<TD VALIGN="top" ALIGN="center"><B>BofA Securities</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Jefferies</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Cantor</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Lead Manager </I></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Oppenheimer&nbsp;&amp; Co </B></P>
<P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g110733g03v83.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g110733g03v83.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[16D4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %8B^51(X0DE-! 0      $8< 5H  QLE1QP"   " ' < E  "')R-C$Q
M-3<Q' (% "5-:6-R;W-O9G0@5V]R9" M($EN;W9I;R!3+3-!4U(@,BYD;V-X
M.$))300E       0^RBL9J0'U%;KVWH;>!;?ZCA"24T$.@      Y0   !
M   !       +<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E
M96YU;0    !);G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;
M   +<')I;G1E<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B
M:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7
M   !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L
M.$))300[      (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,
M   7     $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP
M $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B
M;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC
M 0       %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O
M=6) ;^            !";" @9&]U8D!OX            $)R9%15;G1&(U)L
M=                $)L9"!5;G1&(U)L=                %)S;'15;G1&
M(U!X;$!8            "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0
M  !09U!S     %!G4$,     3&5F=%5N=$8C4FQT                5&]P
M(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D            0
M8W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P
M       ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO
M;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^
M-0 "  $#O_XU  (  3A"24T$)@      #@             _@   .$))300-
M       $    6CA"24T$&0      !    !XX0DE- _,       D
M  $ .$))32<0       *  $          3A"24T#]0      2  O9F8  0!L
M9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:    !@
M 0 U     0 M    !@       3A"24T#^       <   ________________
M_____________P/H     /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H   X0DE-! @      !     !   "0    D      .$))300>
M   $     #A"24T$&@     #-0    8              #0   #3
M  $                          0              TP   #0
M             0                         0     0       &YU;&P
M   "    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P   #0     4F=H
M=&QO;F<   #3    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC
M90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M  9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D
M     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/
M8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,969T
M;&]N9P          0G1O;6QO;F<    T     %)G:'1L;VYG    TP    -U
M<FQ415A4     0       &YU;&Q415A4     0       $US9V5415A4
M 0      !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L
M 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%
M4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M
M#T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU
M;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO
M;F<         "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L
M;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #
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M# P,# P,# P,# P,# P,# P,# P,_\  $0@ )P"@ P$B  (1 0,1 ?_=  0
M"O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
M         0 " P0%!@<("0H+$  !! $# @0"!0<&" 4###,!  (1 P0A$C$%
M05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D
M1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F
M]C='5V=WAY>GM\?7Y_<1  (" 0($! ,$!08'!P8%-0$  A$#(3$2!$%187$B
M$P4R@9$4H;%"(\%2T? S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D
M154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=7
M9W>'EZ>WQ__:  P# 0 "$0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  T -,# 1$
M A$! Q$!_\0 '@   @$$ P$             " D' 0(%!@ #"@3_Q ! $
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M)--3<L<ORQ?EB**S.N/#/OZTHWCJ'V4I3E 1]C 4!*.Q,("&S"(_2&A #!Y
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MS_5*J_RKZQF/A&1GN/7&7,4*U#X[UAC6QS,#8E&Q VJ5D>SW=J154Q= D1I
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M?<X]E^]-MU:OE6@+E3)AA8:I9XEC-UV:C%A78R47(MDW;1T@?L(9)-1%4@_
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M=U-/7\<OS3JTPT76@ -%UH- (=A?(!]@^P     &M;WU:5?TI7.E*YTI2?\
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M9UQ>0\S]A61]:PPGX.313F#SDO'?;HO:90POGF^W9M)AHX"!5!V!!+M0RFR
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MS!*AB>%H^/Y,M5B+CC>S9@YA4S*<]<X*.0>,I2L8]J,)CQW-W.2AGLM6(=C
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M1/Z:Y*$4[Q;("G:@_P!?+W_=-<)["(^XB(B ZV&QV #K[@70:]P#0=*M1UF
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M*[1R23DY)"CJ=QC7?38;;\Z["E*0-%#0?Q$1_+8B(B(CH \B/5P-=-\9[S@
M GO. !DZX IG/U/S))QW:DG TUJ[I2J"&_S^WL(A[#L/8?\ G^8>!V'CI2M$
MOV+,8Y6C64-E#'5%R1$1SX)./BK[4H"X1K&1!!9J#YFQL,?(M6SP&SAPV!PB
MD18&ZZR/?\-0Y14K<63!C&LVD?',VK!A'MF[)@Q9MTFK-BR:)%1:M&;9 A$6
MS5LB0B+=NB0B*"1")I$(0I2@I7U  ![?]1$1'^(CL1_X_;QTI7S/63.1:N6,
M@T;/F+ULX9/&;M%-RU=LW:1D'31TW6*=)PV<HG,DN@J0Z2J9A(H0Q1UTI6N4
MF@43&D$E5L<TJI4"LH.'+M"NTJN0]5@D7;PX*.W*41!,V$>FX<G #N%B-P46
M, &4,80#I2ML$ 'P._S\"(?]0$!_X>W2E8F;K\#98IY!6.$B9^$D41;R$--1
MS.4BG[<1 10>QSY%=FZ1'7E)=%0@AL!+H1Z4H'+EZ7W!*\O5G\MQZJL:LNH*
MATZ>^L-$9E,(B82I1],EX)B@GLPB":+=,@?8O4P-?'?&E*I3O2]X)4AZB_BN
M/E8DUT#E.4EPD;'>V9S%UV_'87.8G6+DI=>"+MU" .Q[=COJ[<A\M/E2CB@J
MY7ZO$LH&LP<17(.-1^7CH:!CF</%1Z "(@BQCXY%LT:) (CVIMT4R%V(   (
@[4K,  !X   -B/@->1$1$?XB(B(C]Q$1'STI5>E*_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g113891g51m17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g113891g51m17.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P C,# 1$
M A$! Q$!_\0 'P !  $$ P$! 0            4$!@<( PD* 0(+_\0 ?!
M  8! 0(&"P8+#PX*!0H' 0(#! 4&!P ($1(3%!8A50D5,5%6E)66T]35(D%4
M5V'1%QDR4E-QDY>QTM88(R0U-F5F<G>!A:6UMM<E)C,X15AD9W1UD9*AP31"
M1$9CA(:TQ,4*)V)VPS=#1TAH<X.'QO""B*:RR.'Q_\0 '@$!  $% 0$! 0
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MR,^[7^-(D"/9Q*B-W)F(TM#<E3RXQM;DV1-4A (,=J5T<0.LAUQ:^D;8BR9
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M-MMA]85&&NA3Y4PIP2!T2'4=(RX5)R'K4UM*R!6?U%Y%_P EK7\M:M/LD_\
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MY^Y[E5UDC9U9=FT\_NUFW5M74TI7Y/\ 4&_:F_ .E*_GL;1_]L/GG]V?*/\
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MEUW?/QV<)Q=4,XPMJ4I7$6WG=;6I<3Q)<1UI$!;CRQ':6Y%#;K;J9*%PEI@
M)CL,)1TTIW&TS-3^!;LM:D3D/?D+>$(G&X-S6'G+DAIALR7D-3"ZRZRN*MNX
M)<N)*Y4J2IW\0=ISM *5L(W!]I9QU=BF,26#:U7(/:6138O;@^(Y>,Y 9$PN
MW"MJ3(\6(L N$H=N4P 9TZ.:LEG"$L2R]BRUN/2WW7_&7+E9_&65.MV]LH;<
M:4S]+0(*BVDI.HJ0L@Y(0 B/8ZA*@]!@B\M,0H[,<1&[1?O%'DLNW-X..-/H
M?/2+5<$!U25CI$Q4 [77#6,;Y5\Q7R:":=X@NL:J"+E+B&%'LI4QY9,2LVH4
M3#& (H-'$NM'1*&[='0+*)B2G6+'E75W5KNN%[7&\61B>SO#60=9V[P,_I<=
MB,DY>,'UZT,)>?7GF]*<??(27=1//WBQXRO$OQIW!]]85JN)U&;%= /ILF1+
M4"3%S*&UR5,1D9?2(;4:,"L,ZZK*^A%ECXL,A^95D]F:V7IGPUY0V/X6@?**
MU7I.Q=Y+8C^ [G\EI]"++'Q89#\RK)[,T],^&O*&Q_"T#Y13TG8N\EL1_ =S
M^2T^A%ECXL,A^95D]F:>F?#7E#8_A:!\HIZ3L7>2V(_@.Y_):]UVR(\:16RY
ML_QLHZ;1LBPQ)1FKZ/?KI,WK-TA ,DUFSMJX,FNW<(G*)%45DR*)G 2G* @(
M:^8N,'$.XMQ0ZTM#C3N(KVXVXVH+;<;7<I*D+0M)*5H6DA25))2I)!!((-?7
MG ;:V,#X-8?0MEYG"N'VG674EMUIQNTQ$K;<;6 M"T*!2M"@%)4"" 016Q?;
MR%ZXB_*#3TVN=KJ\QO'$4[>0O7$7Y0:>FTIF-XXBG;R%ZXB_*#3TVE,QO'$4
M[>0O7$7Y0:>FTIF-XXBG;R%ZXB_*#3TVE,QO'$58&4:S4\J46=H4O8VL?'SX
M1I7#^/D&9))B,;,1\NB\BG''E,PEVR\>DM%2B8BM$R)&TD@119HF0RFL-XXB
MM0938CQY.0UM@YC*JCU.[-XQM/3?)HY*RJ&9[0-\VA'\HU=EF30:-@E[#?7\
M2YF%:ZX.@P9( T02:.Y*.=JKK#][QW^_GE_QK9G$>/:[BHUN4;W&+DAN$R6>
M>-$!(RC6,DH9VK(+QQ9.<L,P@E).7AEU8SMV:"8J)\;#Q$:Z?3+F4536&\<1
M^'X>Y69.WD+UQ%^4&GIM*9C>.(IV\A>N(OR@T]-I3,;QQ%.WD+UQ%^4&GIM*
M9C>.(IV\A>N(OR@T]-I3,;QQ%.WD+UQ%^4&GIM*9C>.(IV\A>N(OR@T]-I3,
M;QQ%='F8>QU9!R[E*ZY-ALH8JB(NWS)Y)E&3,E-IRC1(B*#04WA&L,Y;E4$[
M8QR\4NJ44SD'A;Q$ _&FD?P;,58SQGB#$D&^X?B1;M+1(8CRS<?&&DIC1V"E
MT,P76PK6941J+4,B-H.8'[JT9>%5@[!&C_#&$;AA[$DJ;9("XLB3#%K\5=6N
M7(D!3/3W!I[5"7DI.NV@ZP.S+(FP4NQ591(.\<PX9'I]Z4L7R=^!#O:X!?@?
MXW5GEB?"NW+K5=^S_9O=7;+\-# 2DD#"^+??%FW'^5*DTNQ;Y,3W;\OX='=N
M[DG/^]N_6/Y-83G@;XZ621BC"8SS&U5X[<_Y,[ZU[OABX&<.?I9Q4.K9E9SU
M=_HE_=4D3L8N22[M^6\/]&_N2D][^_\ 6,._K#<\"['BSF,581]]5YW#^2SN
MK$/A>8'((]+>*?ZMH^<ZD$>QHY&2  '+.(1W '<E)WY?UD^76$YX$F/UDD8L
MP>,SGM5>OFJL=?A;X)7_ )N8G&P#JM._/ZI5(D[&[D,N[?E;$G1O[DI.>_O_
M %EUAK\!S2"<LL6X-V;U7L?_ &HUB*\*_!9&0P]B;;O%J^<:_0]CPOS5TR;&
MR?BQ07@N !5.1FC)(\0D*N]8PQ <$%-_ 3Z!WGZ-8KO@*Z1',\L78+'NKOG=
MNM'=YZQU^%5@U6P8>Q)U':1:NW+=<#_QV[JG4>QYWQ(=XY2Q2/3OZ)29_P!\
M1K7.^ 1I'<ZL8X)&PC:J^]O^R*Q7/"CP>L9"P8B'NBU]W\?[JD2=C_O)=V_)
M^+.CO2DQ[^_]:-8;GXG_ *25]6-,#C9VJOW8<_J16.?"=PB?V!Q#U[K9N _=
M_=5:38)NQ=V_)V+N[OZ)26^3]:=8R_Q/G26KJQK@;JR]E?\ O_D>L=7A+83(
MR%CQ!UY]5M[_ ./U5I[!]R(.\<FXQ_>DI4?>'OQ@=_6.K\3TTFD$#&N!/?7B
M ?\ V8UC+\)+"JL\K'?MNS;Z'#LR_=IJJ3V%[@3?OR9C(?X2E/D_6WY-8Y_$
M[M)Y)/IVP%M.?YIB'YDK&/A%X7))%DONT_R=\MJJ+L.VXN[_ -9>-!W#O_3&
M3[^_J[6.K\3ITHJRRQO@'9G^GQ#W?R)6*YX0>&5_L->QE_U?W_QSOKY'[&%K
M=MDW(9#QTB!Q5)Q2TA)%5+Q*QT=XE[7#T'%/ADZ>DABC[^[6.O\ $X]*:L\L
M<8 VG/:O$6_/ZAUC+T^X;6/\CWL=F1$ '8>W\>;*F4]C"U$#<.1L;C]J2D?E
M_6[Y=8BOQ-O2HK++'6C[9GUKQ'W?R'6,O3MAQ6?Y$WD9Y=D#LR_CE<Y=C2T
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MIFN*432#(+J4,_;V1W7SP]KLSY&S-:O&SDP^6B#@@F<!<QT"\"/:R*;"1<3
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MT2^#AHQQ?HWPCB:\PKLY=;Q;7),U;%WD1V5.IF26 6V4 I;'1M(V#9GF>VK
M:=D@VEUN#PWM#Z1 !W4.&#N_O:\MD>%5I=;]C<+(-IZ['%/41O5WUV4KP5M$
M3)4$6^];,R,[Y*/]PJXVW9#-HU41 [VC#NW]RC0P?@+K2R/"WTRM^QN-B]^P
MQ#V9^VK5.>##HH2#E O'4.N]2M^6ZK@1V_=H0X )G5('?N_YDQ =T1W]P-:E
MSPPM-:20+E81D#_F_#[^_NK6.>#7HN2<A"NXVD?Y8D=GNIJX&FW9GI;=PW%*
M[GO4N)#WC?)\FM))\-'3FUK:ESP]L.S/#L,]H'MN^M:]X.FC-'L8=V]^[/G=
M^][ZFT=MW.:F[A.*;T[NY38D.]_['RZU#WANZ>4>QNN'>LC]#<(__P"5:UWP
M?M'""<H=T]^ZO[\MU5([96:5UVSE1Q4N,9BH*0%J464@BNEQ:G&$ H%4]R/N
M.%]2;I#IUKW?#ET_)SU;MAP>R_S:@]G5VU@N:!='B0HB)<\TYY?DH_O]SNJ<
M2VR<T&W<):H#O_8C%![V_P!X@:P'?#L\()(44W?#8R&8_*Q /9WFM>[H.P"D
MY")<OA-_<.ZI=#:]S"H "96I=(!W*G%AW=W<]Q\NM:[X>WA$(SU;QAGJ/^:\
M ]@._OK7O:%L#(UM6+<-A/7<7CV9[=E75 ;7F2FLJR5F(VIS<:"Y0>1W-]JQ
M67;[PXPK9VSX!T'(D$014.FX2*IP14;K% 2#EX>_%#=.MMO,"3?FL+8DM"9#
M8N%H%C1;7Y44K2'D0YT%Y#D686RKQ9YQJ4PA[44]$D-A32M-<=#6$G(KR(9G
MPI);)9D&67T(<VZI=:=24N-9Y:Z4J;64YA+B#D1VNHL8U9%)8(UJF"J2:H)J
MLT"*D!0H&X"A. /!4+OX)R[QX)@$-_1K[B1WA(88?#;K0?9;>#3R.C>;#B$K
MZ-ULDE#J-;5<1F=58*<SE7Y36G46I&:5:JE)UDG-*M4D9I/:DY9@]HR-<G:V
M.^ ,O%4/1ZFJVG:V.^ ,O%4/1Z4J!K,>P/"M3'8LS&%:0WF,V1,([I%V ;Q$
M@CT   '>  #N:5:GV(_#MJ>[6QWP!EXJAZ/2KJ=K8[X R\50]'I2G:V.^ ,O
M%4/1Z4IVMCO@#+Q5#T>E*=K8[X R\50]'I2H&3CV 3%;*#)H!3NI(#E!LB &
M (IR( 8 )N-N'I#?OW#TATZ50]:?=_N-3W:V.^ ,O%4/1Z56G:V.^ ,O%4/1
MZ4IVMCO@#+Q5#T>E*=K8[X R\50]'I2G:V.^ ,O%4/1Z4IVMCO@#+Q5#T>E*
M@*Q'L#Q"9CLFAS<NF0X1FR)AW%F7Y2AO$@CN*4 * >\   = !I2I_M;'? &7
MBJ'H]*4[6QWP!EXJAZ/2E.UL=\ 9>*H>CTI3M;'? &7BJ'H]*4[6QWP!EXJA
MZ/2E.UL=\ 9>*H>CTI6C6(+'M YNMD[DV*MV(:=A&OYFR7C1EBUWBB5G[W/5
MS$5XM&+;/-S.0?HA0S:N6BP7*J2LQ7F#6E/XR'JX1C650F)-^X=,=A(;BQ4)
M94TZY)7'COE_IM5ILR&D/!M+.H=8(2O54YT@S6% ) &:L)M;[RBXEQ"64NN(
MU"WZY24**,]<G82H']*1EEM/48_">0,N9&VBLY1<U;:HWQ?C7*EKH<'0F&$W
MI'CJ*A*?0)!K(2.8CVY6*)-#-W!PX- DJA'+B,:% @II<-V$,PQF6XD=MA\2
MY$-,U4@NJZ#5Z=QHM:@CJ2%^L!R+PS2<\@!F<UB++=C2K@I^)XJQ<!;Q&#K(
MFEPL%[I>@+HD&, E252 ST0=4VUKZZP@X9V0=J#-6:,W6RL6-C 6['+&0VIX
MZ=>Q."KQ0&F()O#6T,;&6*:X?*<Y*2%'RP[R91TIV;DFM8:MY*O2=3>*NQ1:
MNC-$L^?!8BL(6E)0XI,%2 J0TX7T2HC<AQ70CZ8UT:W D%0((.WL-:V/)><=
M6E62T)Z8DI:6@-=&XI*$J<.:5E:0"0-H)ZL\JWIV8KB^RYLX8$RI:XZ#)9\D
MX=QO>[$2*C$VD82;ME0B)V4+'-%5'2K9B5Z^6*U;JNG*B* )IG76,45#:Z6T
MEB5)8024LONM)*MJBEMQ24D]Y !/?6:PX766G" "MM"B!U9E()\^=9R[6QWP
M!EXJAZ/6/4M.UL=\ 9>*H>CTI3M;'? &7BJ'H]*4[6QWP!EXJAZ/2E.UL=\
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M7T:_B96SIQ#-9JK"2Z$#7JK#J2RL/$IPCO\ 02[1<)K ?:QA&(2STC+\>^O
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MK847&U)%J*9WM21SI*TG"::B9S)J)J8$Q$0Z9R")3D.0U- Q3E, E,4P )1
M0$ $-9PP9;E *3>,7%) ((QGB4@@C,$$73(@C:"-A%:XX]NJ24JL>"$J22%)
M. <( @@Y$$&S9@@["#M!K\_1ZL_@7A'[PV(?R.U7TEV_ZKXO^W+$WSG5/3]=
M/J)@?[0L(?,]/H]6?P+PC]X;$/Y':>DNW_5?%_VY8F^<Z>GZZ?43 _VA80^9
MZ]ONR;'I3>S)@68<KOV;B3Q327JS6&D'D)%-U'$$S5.C'0\4LTC8QFF)A*W9
M,6K=JW3 J:*1"% H?-C%K88Q5B9A*G%I9Q#>FDK><6^\I+=RDH"G7W2MUYU0
M +CKJU..+)6M2E$D_6; SRI."L(25H:;6_A>P/*;CM-QHZ%.VJ(M2&(["6V6
M&4E1#;+*$--( 0VA*$A(V$YM-.L+#YR3GKVN>S/=P'*NIR'?Q/.G-IIUA8?.
M2<]>TS/=P'*F0[^)YTYM-.L+#YR3GKVF9[N Y4R'?Q/.G-IIUA8?.2<]>TS/
M=P'*F0[^)YTYM-.L+#YR3GKVF9[N Y4R'?Q/.G-IIUA8?.2<]>TS/=P'*F0[
M^)YUBLV2L.$F$*^?)*Q)ITNW;(1I[18RNCK.KNIC5N3BS+AP 5OZ2E/ YQ*0
M+ 0T:8P. $FF9[N Y4U?=XJYUDB/BHB58,Y./EK Y82#5!ZR<EL4^0CAJY3*
MLW7(51X0_%K)'(HF)BAPB&*8.@0'3,]W <J9#OXGG59S::=86'SDG/7M,SW<
M!RID._B>=.;33K"P^<DYZ]IF>[@.5,AW\3SIS::=86'SDG/7M,SW<!RID._B
M>=.;33K"P^<DYZ]IF>[@.5,AW\3SIS::=86'SDG/7M,SW<!RID._B>=.;33K
M"P^<DYZ]IF>[@.5,AW\3SKI$S#V1#(N(\I73&</3*_)1E0F#1K-^_LEY1>.D
MCH(.Q4<),+ U9D4X;DY=R""91 H&$!.)C#^-M(WA*8GP7C*_X:A8?L,N-:):
M([,B49X?=2J-'>UG0U)0WK!3Q'K4I&21LS)-?N;1GX*F$\;X!PSBZ?B7$4.7
M?(*Y3\6&+=XLRM$M^.$LEZ*X[JE+05Z]:CF3MRRJP4NRG954'<- JP=.[HM.
M1/D_9/\ +K@E^&%C-.?Y5<,'++MN?;E_'*[5?@78)2,_3;BH]VK:N\_N*I%'
MLH.4E-V^AU@-^[N6C(7O[OV3_+_LUAN>&7C1!(&$\+'('K5=.S/^.=U8+O@<
MX*;.7IJQ2>KZECK_ .Y&I,G9,\GFW;Z-6^G?W+/D'WO^TWR:PG/#4QN@Y#"6
M%#[JKKW?QWOK#5X(6#0"1BC$_O\ H9\B%2"/9)\F*  C2*Z&\/>L^0/E_9+\
MFL)SPW<=() P?A(Y'+V5V^75CK\$?!Z.K$^)CU'JMG:<OW'4B3LC>2#;M]+@
M.G?W+1?O>W_LDUAJ\.;'B<LL'80VY]:KOW?QZL17@GX1 )&)<2>^+:?_ "@K
M]_3"<AN7+1R:FP(&:"N) YR7@XCQZ8I#P5#V RB6X Z>*,3AA[D_"+T:QG?#
MLQ\WU8-P>?=5>.[=/[Z@7X*F$T[1B7$?4>M-N[,OXIF/>J<0[(+D)4=PT^%#
MIW=%HOG^^Q#K6N^'SI!;ZL%8,.PGV5Z[/]H5BN>"WA5 S&(\0GW1;^[^*]]2
M!-OF_FW?UI0X;]__ #HO7O;_ -D/R:PU_B@>D-'^9&"SL]M>NTY?5"L97@Q8
M6'^<6(.O+J@;@?W-WU6$V[[Z;NU2([N[]4]Z^3]D6L=?XH3I%3G^4;!1V9^S
MO??_ "AW5CJ\&C# &8Q#?^O= [_XM54GMT7LX[AJL5^]9[S\O[(1[VH#^*':
M1@"?2+@G9^_O?SA4"O!MPRDG\L%]V#/J@[L_W/56GMPWD^_?5XP/^T]X^3]D
M'RZQS^**:2 2!@3 ^S9[*^?.-8Q\'3#8) OU\V;.J#\GJI+MM7<V[?6(WI'=
M^J>[]_=X0:QU?BC.DE.66 \#;<^M=][OY2K%<\'O#B.J^7LY_P"I=_\ %^[N
MKZPVR+FU;D;EK<<)2"J<!+8[BB'YZJ=40XM&<(F&X5! 1*4!,(<(V\YC&''7
M^*/Z2TYY8"P+L/:J_;\OJG6,O0#AY'5>[SED-F4/M/\ H*ET]LBYG#>-=8!_
MVFNOR_K_ /)K$5^*3Z34Y98 P'MSZUW[N_E.L9>@FP)SRO-Y.677XIVY?P%<
MY=L.XB&\:ZR[H!^J>Z^_N_7[Y=0*_%+=)Z<\M'^ MFSV=_WY?5.HCH+L(RRO
M-WV@'JB=O_8UMIL_91:9HCIPKYK.PLW73L!>IM+78'$>[;28.^2N&IEG@+('
M*HR<)+ME3K<$ 15374!4Z:'[C\%/PGCX15JQ.W<L.LX<Q)A!VU>B+,&0Y+M4
M^%>4SO$ID)4AM,B,ZAVVRV94)]<C4 COM2G0^XU&\FQ_@48,DPBS-7-A7 2.
MA4ZD-R&G(I9Z5MT(44.)*7VU(<0$9^O2IM.J%+V(YM-.L+#YR3GKVOUKF>[@
M.5>>Y#OXGG3FTTZPL/G).>O:9GNX#E3(=_$\Z@Y&OM22]>3!].B"KF0 QCV"
M8.<O C'!P%)0ST3I"(AN,*8E$Y!$AA$HB LSW<!RJA S'7U[SN/?4YS::=86
M'SDG/7M,SW<!RJN0[^)YTYM-.L+#YR3GKVF9[N Y4R'?Q/.G-IIUA8?.2<]>
MTS/=P'*F0[^)YTYM-.L+#YR3GKVF9[N Y4R'?Q/.G-IIUA8?.2<]>TS/=P'*
MF0[^)YTYM-.L+#YR3GKVF9[N Y4R'?Q/.H*MU]JM$IG,^G2"+V7+P4K!,)$W
M)R[Y,! B;TI0,8"@8YMW"4.)E#B)S&$69[N Y4R[SQ/.IWFTTZPL/G).>O:9
MGNX#E3(=_$\Z<VFG6%A\Y)SU[3,]W <J9#OXGG3FTTZPL/G).>O:9GNX#E3(
M=_$\Z<VFG6%A\Y)SU[3,]W <J9#OXGG76?MY;5F8-F2UXVJ6%<1*9AD;?6+-
M:Y\DODF?@EH2,AK=0*4S7:H%D4 >(*S=_BR2*Q5E!C69E)5VDWAX^5D6=P&8
MSS VY>Q34:R4D9 D9>V([<N\[\^[SZ.5;LL6>V4M#N<O;-'-*D2CJ!01GH/*
M5GE7+]24DK$H:*AD22#TLG8I" Q]D0E<AFR2KB0M<5 0;\T6WLC"1-FV^*U-
MF,Q')"6/&-=IMTH!0F0I"O%^E.?K&5/ZC;KAS#:5ZY! (K#G2G(L5Z2AE3W0
M!+KC:5J*U1T.),GHQD-9U$<.N(1^G*-7,%0-=_\ "-*]986(L4%/R\M!ST8P
MF8:48VF9<,I**E&J3V/D&:Y'XD6:O&BZ+ANL01*HBH0Y1W&#6&XAQEQQEU!;
M=:6MMQM: E:'&U%*T*!&84E0((.T$9';6:VIMUM#K:PMMQ*7&UI42E:%C-*D
MG/J4D@CN-4DCC"F3"Y74M%FE'1  I',B\=OER%*("4I5G*RJA0 0 0 #  "
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MG.:,^PSGFO9O9&F1[N(YTS'?P/*G.:,^PSGFO9O9&F1[N(YTS'?P/*NO:V[
M^SEDVT3>0+F7+;>TVA\I(3",625;1Y'  5NGR5N:FO#))BW01,)1<JCPQ,/"
M#?P0\+Q3X/& <7WVY8ANSE]%PNCZ9$H1+G'98#B6FV1T3:H3I0G4:1L*U'/,
MY[=GZ%PEX3>DC!F&K3A6T-8=-LLT94:(9EJDORBVIYQ\],ZB>TE:@XZK(AM
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M1+O&R109M3RLTNV8J2*5=555(A%GAF0N.)664,B9<X\<HX/ID=XXIYTS'?\
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M4N*:!UP@JV!92$D[ <ZO+;@0'2A8;*BD.%*M0J S*0O+5*@-I .>6W*JH1W
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M .O9_@P;_P#3U;*G9?\ :V9@X,FTP^<5ECN!!;'2:@$,8"$$B?\ 5@. D $
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ME%EU5#%(FD0QS"!2B.KD(6XM#;:2M:U)0A"02I2U$)2E(&TE1(  VDG*J$@
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M\<#SIR*QCW+!'CT;_P!(1[G?_3?N=(?Z=-FX\1RIMWC@>=4#QQ(1[B*9O[E
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MH% .>!L2$?ZW)_Q;4,OE;L61=_&[.F83;@'N&F>_T_\ UFR[_P!_5XM&E;,
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M"(Z^9.+VVV<68H99;0TTUB*]----H2AMIMNY24-MMH2 E"$( 2A"0$I2 E(
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MP%.;\#U)$>367H=*9#<. IS?@>I(CR:R]#I3(;AP%.;\#U)$>367H=*9#<.
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MF)R&9CVH\_.F1]L> Y5.]J)?PJE?$*_[(TS&X>?G3([SYN5.U$OX52OB%?\
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M2R5Y$NI&9*"H)*-;(9!.1.W:G,#,I).KV2</09$6*IB0LW!$,IF,H6%,HG.
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M2E-*4TI32E:?Y2_5W._P9_(T?J9'L1[_ -TU"OV1][[@K<#4-34TI7PP")3
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M<@<AAC15U?4+%G?_ #WJ#U$,)ZN?C^(.O+\]V[=_U569<'[6%HOUZBZ;;:_
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ML;1>ASKK+E1G2T[<4.MEQEU"RVZA#B"=5:4J! QG]*>V]_B)>^=M'_*/6_\
M5]T6>4+WP->OD%<S]#1IE\EF/A_#_P YT^E/;>_Q$O?.VC_E'IZONBSRA>^!
MKU\@I]#1IE\EF/A_#_SG50U[%3V0%BN5RRPE*LW)"J$(X:W.F-UR$62.@L4J
MJ5E(H4JJ*BB*A0, *)*'3, D,8!L<T\Z*74E#M^6X@D$H<LEX6DE*@I)*56\
M@E*@%#,;% $;0*O;\&S32RL.-8:;:< 4 MO$-A0L!:2A0"DW0* 4A2DJ .U)
M*3F"156;L7/9$#I.D3X?L!T7O0]1-?*D9)V'*'+K<Z3&T"1Q^BGCQS^>@?\
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M9?)9CX?P_P#.=/I3VWO\1+WSMH_Y1Z>K[HL\H7O@:]?(*?0T:9?)9CX?P_\
M.=>NK9J92N.]G[#-$ML'/QMGJ.-ZE7I^/)"2;XC*6BX9JT?-BO&#5RR=%1<)
M'("[5PL@INX22IR"!A_ ^)I<>XXCQ!<(;G2Q)][NTR*X0ILN1Y4^0^RLMN!+
MB"MM:5:JTI6G/)20017TLP? E6G">&+7.;Z&;;</6:!,:"DNAJ5#MT:/(;#C
M16VX$.MK2%MK4A0&LE1203F[G*R^ 6'S9GO9^M)D>[B.==%F._@>5.<K+X!8
M?-F>]GZ9'NXCG3,=_ \J<Y67P"P^;,][/TR/=Q'.F8[^!Y4YRLO@%A\V9[V?
MID>[B.=,QW\#RJC=RD&_.R4?04J]4C7?+XY1W4)AP=@^!LY9 ]9&6C#F:NP9
MO7C3E* IK<F=N4.'Q2ZI#LCW<1SIF._@>56PI7,7K$!)7&D8JF"+=N":F,3'
M("#-HT8-$ (:!$H(M6+!BS;I[N @T9-&Z12HMD2$9'NXCG36]W@KE1C7<7Q9
MGQXS&D;''E(QQ"29V.,3-#2,,\3;I.XA\9O IB[C'231JDX8.!4:KIMFY%4C
M%13 K(]W$<Z9^[P/*J9>HXD<K/G#G%4(X<2;'M9)+KXJ*JM(1O(TX_M>^54K
MQCNV/($4F/)%S*(<C23;<7Q)"D!D>[B.=,_=X'E4Y"-Z36E7R]<I8U]:44!6
M36A* ]BE9%4%W3H%'RC"&0.[4!R^>N0.X%0P+O'2V_C'"QCLCW<1SIG[O \J
MN#G*R^ 6'S9GO9^F1[N(YTS'?P/*G.5E\ L/FS/>S],CW<1SIF._@>5.<K+X
M!8?-F>]GZ9'NXCG3,=_ \J<Y67P"P^;,][/TR/=Q'.F8[^!Y4YRLO@%A\V9[
MV?ID>[B.=,QW\#RK1ZP;$FS'D":>72]8_O#NX3W)G,\Y;N\@,T%7J+5!IO3:
ML#)LT2E2;I%X+<A2")1-TB81'Q[$6@?1MBF\3[]>;1*DW*Y.I?EO-WBXQT..
M);;:!2RS);;;&HT@:J4I&8S(S)KV_#7A%:5,)V&VX;LEZAQK3:651X,=RQVN
M2MII3SCY2I]^(MYP](ZLZRUJ.W('( 5%E['QL=%'>7&]^#?W?ZJ9+'_XNM$K
MP8]$"L\[!-V_R_=_EM;H^%3IG(R.(('VNV?Y%5078"V0"?4XYOH?PEDH?PJ?
M+J%7@N:'%>RP_./^\%X'W)HJ!7A0:8E^RO\ !/\ N_:!]R%W55%V#MD@N[@X
M\O@;NY^C\CC^$^H5>"KH75UX>GG_ 'BO(^Y-J$^$SI=.>=^A'/K_ " M/R.N
M<FPOLG)_4X]O8?;?9&'Y/K^]J%7@FZ$EG-6';A]L=Z&_^/=]1GPE-+2L\[Y"
M.?\ (5J_NB54%V(=E,O<Q_>@W?X9D4?PFU"?!'T'*Z\-W [<_P!$M[Z_>GU&
M?"/TK'/\FX6WK_(.U]O_ '2J=QL4[,I',9R/']XY/RQ7MD)G>01$&G:]Z*0E
MX9^%OY>#+?Q7N]V_A?G7&:C5X(.@M?LL-W$_[RWS^Z=WGKXYY5$KPBM*IR_)
MN'EV_D':\^[]:?A]R7)L9[+Q-W!H5X#=_A.0Q_";Y UC*\#?0*LYJPS<C_O/
M?1_Y^HSX0FE%77>HAS_D2V=_\4[S52&Q[LRE[E$NX=._^SY![O[XZA5X%^@!
M77A>Y]O^=-^[?]H5&=/^DT]=XB? MM[,_P"*]YKE#9$V:2]RC7</_P 6_P#O
M?;#49\"KP?3UX6N?VU7_ .<*C.GK26<\[Q%.?7^0UM^2UREV2MFTO2%'NV_O
M\9?OFW:L^@F\'H_YJW/[:\0?.-6'3MI(/7=XOP/;ODM<I=E#9Q*.\M)NP?\
M\=]'\)=1GP(?!X)S.%+I]MF(?G&HE:<=(JCF;M&S_P"J+?\ )JY V5=G0 W!
M2;K_ *U]_%U8? =\'4YYX3NASZ_RV8A^<JC5ILT@JSSNL8Y_R3 'W(U4L?LM
MX&+RSEE*N9=S]SR/@C>!WL?< W$W */NMW"W\/\ //K@[FHSX#/@Y$Y^E.Z_
M;;B(?=N/G\YJ,Z9\?'KN<;K^I4'^Z/\ =J5+LQ[/A/J:9= _>O8_A)\NHE>
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MS^DTI3G '4M@\EG])I2G. .I;!Y+/Z32E.< =2V#R6?TFE*^#82@ B,-/@
M(B(QA@  #I$1$5=P  =T=.KKI7 E:V:YU4D(^8650$A5TTF15#HF4+PTRJD(
MN)DQ.3W9 . "8ON@WATZB0^PXXXTV\TMUDI#S:'$*<:*TE2 X@$J05)!4D*
M*D@D9BKBA:4H6I"@AT$MK*2$N!*BE10HC)82H%)*20% @[151S@#J6P>2S^D
MU+5M<*UI;-DE%W$;--T4BB=599B"229"_5'4446*0A2[AWF,( &[I'50">H$
M^YM^Y5"0!F2 .O,D 9#K.W=4%&Y0J$RX%I$/R2KL X0MHUQ'OG %WB'"%%J^
M54 -Y3!O$N[>40[H#J]3+J!K+:<2G;ZY2%)&S//:0!LR.>[(U&E]A:BE#S2U
M Y%*7$*4">H$!1()W5<86$H]R&L _:C##_\ $U'4M.< =2V#R6?TFE*H92Z1
M<)&2,U--I*(AXAB[E):6DVR3"-BXR/;J.W\C(OG3A)JR8LFJ*KEV[<JI-VS=
M)1990B9#&"Y*5+4E"$J6M:@E"$@J4I2CDE*4@$J4HD   DDY 9T) !).0&TD
M]0&\U8..=HG#>822RN)+_5<I)0!F1)U3'5GK5V3A3R17)XXDL>M3$F6.,_(S
M>&9%>"B+HK1R* * W5X$\F',AE"9<23%4X"IL26'6"L)U<R@.H05 :R<R,\B
M0#MJQ#B',]1:5ZIR.J0<CWY5DSG '4M@\EG])K&J^G. .I;!Y+/Z32E6V_R?
M6(MVJPD E&CQ#B^.;JQRH*)\:D19/A !A#W:2A#AT_4F#5P23M \XJTJ .1/
MF-9$U;5U:YTNVUJL94M&/5Y6/EK-;YR5L(+PS627Y"H=>>?M86RRTM;)MRYE
MV< Q20;(1L/#0L,QCT8I)!JCVL:E\_L]TMUMQ-<K"N2Q*N5VFRI^O$:D+Z$J
M7.?:AW&5*NDUQR4S!92VVB/#APX;+"(J$-H,9L=#,B29-KBW!++C4:(PU'R>
M4VG7 2PA;T=IJ(PA+2Y#A4I3CSS[RW%.J4L](JMBC_4&_:F_ .O0*YZOY[&T
M?_;#YY_=GRC_ #XG=?4[ OZ",&_T5P]_9$.OC7I(_P"43'O]-,4_VY.K#&NJ
MKBZ:4II2FE*:4II2FE*:4II2O?UL:?VI^SI^X[0OYO,=?*S&?Z,,6?TEOO\
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MM-.R$-1D/NMME*''DQHZ75 K2RT%!"=A.26GKR$\VWGY3:Y[9N/$<JZG;O'
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MXA,A"%4_LHE*!3', :M6ZIP +)(!S ]: "<\^I(Z\S^ %7)1JDD':>O/,]0
M'6H]0%9!Y):>O(3S;>?E-J/9N/$<JNV[QP/.G)+3UY">;;S\IM-FX\1RIMWC
M@>=:KY(([)=)DKUPW<N0[7<8LW:J-$3[XIB). W4=O#I\%,2$-O<J<,Y3'#@
M 8$RRI]B/?\ NFHE>R/X=E;DZAJ:M,(N??1>U'VEL3J\JRUA<S9*^PD9/'<-
M5D*BC"S;IH_BJK5\D-K=9FQ5H4C3G5<J)8W4<[64:)J5Q-TGR;R"-.?C:2_$
MK@[>ERI[DWQ!B1*P_$MB+4W"ENM/QK7;<0MW6Y-AR&EKT3N]DN#L=Y9:2JWI
M<26^Q=CH=PQTT=$$,QPR9#C;-P>E&67F4*0[+DVY42,HA\K\5ASHR'$)"R)!
M0=;<T_U!OVIOP#KU^N.K^>QM'_VP^>?W9\H_SXG=?4[ OZ",&_T5P]_9$.OC
M7I(_Y1,>_P!-,4_VY.K#&NJKBZ:4J]<>VAC3;2VGY&+"::MXZP,QCC"@4JCB
M7@).(9NA%RBX1X46\?-Y9'A(G,+ABD"9D%1(X2UMW@NW&"N(R_XLM;T5SIAK
M9A$>4S(<0-12%9/MM*85DH#4=5F%#-"MK9;@S:[@W-?CB6VAB8UT!U %+DPW
MXS3AZ1#B<X[CR)*<T$E;*0DH5DM.19'+=3DH0T8KC&'1560E"/N1.B,63UY+
MR56E%)%!)LQ(YABQ#B"FR5Z*CW(LXAG<)&,9G;Q31PQFM.S8+@S)Z9-Z?4D*
M8+9<07'6FX[,U@-**W"W),A$J,9;[J Y(<M[+SH6^XAR-O'\2VU^)XNK#\5"
ME(?#X:<#3+SLF1;Y"GT);:2Y%$9<.4F%'97T49JYOL-%$=M;,N0C<QT>-BWK
M!+%409VZK*%:2F 6: ^:K1R\PE#VXA5H]RGSK8Q;Z,(LY;"R;OY6*[9." 9R
M";>)[#UT??;=5?7PVB8N88^JX6EAY,=4B 2EY"O$'7FWM5"^D6RP_P!"@D(S
M7,QB>T,1G64X<C%UVWHMZ9.NT'6U,KDIC7(%3"P;BTP['"G$!I#TB,'U@%82
MC&&0K9&W"8:2$3")P#)K&%9)QJ96'%MQ-(R4D*""K%@P%9@Q"1",B >D<OFD
M,QCHY5XX39HF#=VF ];X[C3\DRG''RZ7B7<U_266=90===U77>A+TCHRAIR0
MZZZEM!<4*T%[N3%SE-/QHB833<<,AA(9R02^^_J)4RRSKLLA\1XW2A;S<5EA
ME;K@:2:L36TK3TTI32E>_K8T_M3]G3]QVA?S>8Z^5F,_T88L_I+??[4E5]F=
M'WZ L$_T2PY_8\.MEM<U77TTI32E-*4TI32E:4/=G;-"<HQG:QF2"K,PC=YN
MYR1BU)_)1LH>5A;!6VT45@:?9+1L1%P<C7T4(QJ_,W?S-6+:[":=LUCL$H[4
M_#\/PX5ME3(N>A*E6H>TSX6NQQ4)&Q\W9N0DC#6"39M$F[R84CTE5DFBLBLF
M9TL@DH9)-54X)\$G!*"E7+I2FE*:4II2FE*:4KS;YPV)-J&^YGR;=*EBMW+U
MFR7*:E(64)9Z0T(^8+NQXIP5L_LS5ZB!^ ;\[<MD52[O=)AO#?\ .W2IH3TH
M8AQ_BJ\V?"KTVVW&[29$*4FYV1D/,K" E8:D7-EY .1V.MH5O%?3711I[T2X
M=T:8)L5YQ>S"NMJL4:)/B*M-_>5'D-E96V78UJ>8<(S'KFG5H/8HU8K38!VN
MT@+P\.O2[A#?_7;0!_!:QUY9(\'+30X?68)?/7^S.&QVY]MX%=?*\(W0NX?6
M8V85M/[#8C'M=]G&XU<S?80VL"& 38C> &_?^JNACWO>"TB.M,_X,^G!:5!.
M!7R3EE^3F&!V=]Z%:5WP@]#RLM7&3)RR_8?$/?\ R15R(;#VU,3@\+%#L-P!
MO_KIHP^^'>LXZTSO@O:=U9ZN 9!]E^SN%AU]77?*U;NGO1*H'+%[)S)_8F_C
M?OM57 SV*]IQ(P</%KLO3X34H?\ C /O60?> =:*7X*6G]SV&CR2KJ_9_"@[
M".V_#M-:U[3IHJ4#JXM9/^RK[NR^I>^KB0V.=I(F[A8R=!NW?\XZ:/UO>L0]
MX=:5_P $CPAU^QT<23_O#A$;M]_&ZM4]ILT8*)U<4M'/^2[V.W/MM@JL/LE[
M0K51HDOCERFH]6%HU*-@J1N-<%;.'ADP$L^8"B#9HX4X1Q*003$H&X9B%-KW
M/!!\(Q6>6C:2=N?Z(\']6W^</?6O<TS:-%!0&)VB59Y?D;>MO;]3MV^II#9(
MVAR%+PL<.0W;O^<-1]X1W]R?UKW/ [\) YY:-)1];E^B/!W7M_G%6N=TOZ.5
M998D;.67[&WCO_D[OJ9;[*6T F  ?'CD-V_^[]4'WS=Z>'OAK5N^!GX2RLM7
M1C*/5_G+@P;]^(ZU[VEG1\LG5Q$V=@_8^[CJ]V *F6^ROGDYTTQH2J?".4!.
MK/U8B9 $P )CF[=B/!* \(W! QMP#N*(]&L!/@3^$X^ZAL:,7FPMQ*2X]BG!
M*&FPI6J5K5Z9"0A.>LK52I>J#JI41E6M=TIX#""1?DJ(S.JFWW4J.0.P#Q$#
M,]0S(&?60*[4\/4^5H.-JK4IM\20E(ADN1VLD<RJ"1W3YT^*R;*G(FHHVCTW
M)&*"ARAPDVY1(5-/@)D^UO@_:/K[HLT/8(P'B6YMW:]V&W26Y\EAU;T5AR;<
MYUR1;8;SK;3KT.TLS&[;&=<0G7:BI4VAIDMM-_E?%]XBW[$=TNT)A4>++>0I
MI"TA+B@TPTP7G$I4I*7)"FR^M()R4X02I6LHY+U[)7-TTI5O0']DG_\ WA>_
M]V9:50=:O=_N%7#I5::4II2FE*:4JWK1^E)?\[US^<45I2KATI32E-*4TI32
ME-*5;]7_ $G3_P NF?Y9D-5/7[R?N"J#J]]7W35P:I5::4II2FE*BYN&C;'#
M2U?F6P/8B=C'T/*LQ570!U'2355F];\>V51<H\<V643XUNLDNGPN&DH10"F!
M50HI(4DY*20I)W$','WCMK'Y,*8V2$#-X!=H<'BLAPV4_960GD%W=>D%GRW)
M)A'CW:LA58&04<+\8L:08<N%3E;EXLX5,N2^LE2G5$D*]<<LQK)*3MR&6PGJ
MR%:Z6"'>\L=%/BIY//F-MLSY*-/"$-68^/C;U79YE9F;XAVBMCL]EJ,(UG6"
M2DM(E)9FJ5<7"#2,[:K7 D'W^KJW9]7N=75W5F,ZK20MN:6M=E(0IMSI%:_1
M$I:6EP*2A(=2@9I2E0!ZR1G4)6*3-Q*E99NL;H-XIO)UARNW8.<E-S,4I:P+
M/9M5NV=6]_$*F@WU4ID\L:4>@"2 23Y%H^DUFD9,,\U9@;?P_P#;O'?MJ]YX
M%1*98S UDN+*"<@C5/Z1*?9*7ELW#+]-5XQ>/SI,#-E-G5DY9O@!5P5A>481
MH_;.R5DY32D$ZD=SJ<9)Q3+E+R1**[N6KI)DCAH\D@%*A.9SY_WYU"'E*"4F
MX* 2-366V5+&8.92I#?L3GLR5GD=N>659%J<GD^NP47#,<,H13&,2;%3CT;O
M!&;E(Z<CRR/CR&=/>U[.(Y0HM&I@NX058,T8]LVBRJI-F5*A>#*G5K\94O64
M5%71J.9)&9]=JG+:3U Y@C;VYUBG#YW&1[J38!%2+ADU7?QA72;XL>\51(=R
MR*]2(FD\!JL8Z .DTTTUP)QI"%*< !6,H *4$G6 ) 5EEF =ARS.6?7EG5?I
M5*:4II2FE*T_RE^KN=_@S^1H_4R/8CW_ +IJ%?LC[WW!6X&H:FII2@AO 0'N
M#T#I2L<*X>Q2NJHLOCBE+++*'5665K<2HJJJH83J***':F.HH<XB8YSB)C&$
M3&$1$1UFIN-P0E*$3YJ$)2$I2F4^E*4I&24I2'  D      #(;*P%VJUN+4M
M=M@+6M2EK6N''4M:U$E2E*+9*E*))4HDDDDDYUQ_09Q)\6E&\V(?U35?1.Y?
M5&=]ER/C*M]![3]2[=]A1OBJ?09Q)\6E&\V(?U33T3N7U1G?9<CXRGH/:?J7
M;OL*-\53Z#.)/BTHWFQ#^J:>B=R^J,[[+D?&4]![3]2[=]A1OBJ?09Q)\6E&
M\V(?U33T3N7U1G?9<CXRGH/:?J7;OL*-\53Z#.)/BTHWFQ#^J:>B=R^J,[[+
MD?&4]![3]2[=]A1OBJ?09Q)\6E&\V(?U33T3N7U1G?9<CXRGH/:?J7;OL*-\
M53Z#.)/BTHWFQ#^J:>B=R^J,[[+D?&4]![3]2[=]A1OBJ?09Q)\6E&\V(?U3
M3T3N7U1G?9<CXRGH/:?J7;OL*-\53Z#.)/BTHWFQ#^J:>B=R^J,[[+D?&4]!
M[3]2[=]A1OBJN5"EU1JBDV:U^+;-T$RI(-T&J:***1  I$TDDP*1-,A0 I"$
M*!2@  4  -VL)2E+4I:U%2E$J4I1*E*4HYE2B<R22222223F:ST(0VA*&TI0
MA"0E"$@)2E*1DE*4C(!(      V"N7FG6^I6'W$/GU2KJ<TZWU*P^XA\^E*<
MTZWU*P^XA\^E*<TZWU*P^XA\^E*<TZWU*P^XA\^E*<TZWU*P^XA\^E*<TZWU
M*P^XA\^E*<TZWU*P^XA\^E*<TZWU*P^XA\^E*<TZWU*P^XA\^E*<TZWU*P^X
MA\^E*<TZWU*P^XA\^E*<TZWU*P^XA\^E*<TZWU*P^XA\^E*^!4JR4-Q82/*
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9>FE*:4II2FE*:4II2FE*:4II2FE*:4K_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g113891g94r84.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g113891g94r84.jpg
M_]C_X0Q717AI9@  34T *@    @ # $   ,    ! ,T   $!  ,    ! #
M  $"  ,    #    G@$&  ,    !  (   $2  ,    !  $   $5  ,    !
M  ,   $:  4    !    I $;  4    !    K $H  ,    !  ,   $Q  (
M   >    M $R  (    4    TH=I  0    !    Z    2  "  (  @ .8:0
M   G$  YAI   "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C R
M,#HP-3HQ,2 R,#HT-3HT,0     $D   !P    0P,C(QH $  P    '__P
MH ( !     $   #7H , !     $    Z          8! P #     0 &   !
M&@ %     0   6X!&P %     0   78!*  #     0 "   " 0 $     0
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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MK_XK>A?\7F?]16EG_P#BQZ7_ .%LC_OB75?_ !6]"_XO,_ZBM+/_ /%CTO\
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M]1K'@$0X0DE-!#H      .4    0     0      "W!R:6YT3W5T<'5T
M!0    !0<W138F]O; $     26YT965N=6T     26YT90    !#;')M
M#W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $
M      ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4
M= !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL
M=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !
M   2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB
M<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
M     $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN
M=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P    !29" @
M9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@(&1O=6)
M;^            !"<F1456YT1B-2;'0               !";&0@56YT1B-2
M;'0               !2<VQT56YT1B-2;'1 \-4<)0        IV96-T;W)$
M871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15
M;G1&(U)L=                %1O<"!5;G1&(U)L=                %-C
M;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L
M  YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M        #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO
M;F<      #A"24T#[0      $ .]E'H  @ ! [V4>@ "  $X0DE-!"8
M  X             /X   #A"24T$#0      !    !XX0DE-!!D       0
M   >.$))30/S       )           ! #A"24TG$       "@ !
M  $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M      $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE-
M _@      '   /____________________________\#Z     #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z   .$))300(       0
M 0   D    )      #A"24T$'@      !      X0DE-!!H      T$    &
M               Z    UP    8 9P Y #0 <@ X #0    !
M              $              -<    Z                      $
M                        $     $       !N=6QL     @    9B;W5N
M9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,
M969T;&]N9P          0G1O;6QO;F<    Z     %)G:'1L;VYG    UP
M  9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2    !W-L
M:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU
M;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU
M;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG    .@    !29VAT;&]N9P   -<    #=7)L5$585     $
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M &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '
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MQ &B    !@(# 0             '" 8%! D#"@(!  L!   & P$! 0
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M:"Y3&469H"^J&IA:FJ,OG#Z1+3RY:@;@QK[]U[J^3W[KW5*GPG_[>@?S&_\
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MMQCF;M29VB93(SV<::H1$I"E[M0:35723W X-[CFOF2WB^J%K9LBG4\=) =
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M@-L*GH\)@LAG\'UC_"^X\QM'$;?[9VC5X*HW?D-]9W:5-F=T;5[ES%%D\RF
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MTU)1T=,D=/2TM/$@5(T5410   /9!)))+(\LKEI&))))))/$DGB3YD]+
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?W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
